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 Introduction 
 
     imian virus 40 (SV40) is a small DNA tumor virus, linked with specific human cancers such as 
malignant pleural mesothelioma (MPM), brain and bone tumors, leukemia, lymphoma diseases. Its 
DNA sequences is also detected in healthy blood donors. While the debate on SV40 association, 
rate of prevalence and detection of its DNA sequences in different human cancers including non-
Hodgkin lymphomas (NHL) are at increase, indebt studies on the interaction between lymphocytes 
and SV40 has not yet been fully described. 
 
The highlighted issue calls for further imperative investigation. Hence, this study investigated the 
interaction of SV40 virus in healthy blood donors using three different experiments. Experiment I: 
―Simian virus 40 sequences of healthy individuals from Aviano Cancer center (Italy).‖ The 
experiment aimed at detecting SV40 DNA sequences in healthy blood donors. Experiment II: ― 
SV40 infection of human T lymphocyte.‖ It aimed at investigating the rate of  susceptibility of 
purified T lymphocytes to SV40 infection. While the third experiment-―Transformation of human B 
cells by SV40, a small DNA tumour virus‖ investigated the interaction of SV40 with purified B 
lymphocytes to observe the capacity of SV40 to infect, transform, and immortalize B cells. These 
three studies/experiments indeed, indicated the potential role of SV40 in Lymphomagenesis, its 
relationship and effects with human lymphocytes. Detailed information of these experiments is 
depicted in results session, each starting with a short  abstract.   
 
 
1.1:   The discovery of the simian virus 40, SV40 
 
SV40 belongs to the Polyomaviridae, a family of small DNA viruses that comprises the human 
polyomaviruses BK virus (BKV) and JC (JCV). BKV and JCV infect 70-90% of the adult 
population (1,2,3,4). The family name is derived from the first recognised member of the 
S
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 Polyomaviridae, the murine polyomavirus (MuPyV), originally discovered in 1953 by Ludwik 
Gross as a source  of salivary gland tumours in mice. MuPyV  was initially designated 
'polyomavirus' from the Greek 'poly' meaning many and 'oma' meaning tumours, due to its ability to 
induce a variety of solid tumours in mice (5,6). 
  
SV40 discovery was linked to the development of the anti-polio vaccines in the 1950s and 1960s as 
poliovirus was grown in primary kidney cells of rhesus and cynomolgus macaques, which were 
often naturally infected with SV40 (7,8,9). The virus was then inadvertently introduced into the 
human population through administration of these contaminated anti-poliovirus vaccines. Soon after 
its isolation, to verify whether SV40 is able (i) to transform animal and human cells and (ii) to 
induce tumors in animal models this viral agent was intensely studied both in vitro and  in vivo. It 
turned out that SV40 transforms different types of animal and human cells and induce in 
experimental animals different kind of tumors, depending on the inoculation route. Consequently, 
SV40 became known as a potent DNA tumour virus. In the past two decades, increasing evidence 
of the presence of SV40 in human tumours of different histotypes has seen this 'monkey virus' 
emerge as a potential human pathogen, a topic that is continually under debate (10,11). 
 
 
 
1.2:   Polyomavirus Infection in the Natural Host 
There are 22 existing  known members of the Polyomaviridae, capable of infecting  a range of 
species including monkeys, rodents and birds. The phylogenetic analysis of the polyomaviruses has 
revealed three genetically separate groups: (a) avian polyomaviruses, (b) mammalian 
polyomaviruses linked to MuPyV and (c) mammalian polyomaviruses linked to SV40. The natural 
host of SV40 is the Rhesus macaque (macaca mulatta), but several related species of monkey are 
also capable of being infected (12,13,14).  
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 The spreading of SV40 in the monkey is thought to be by viral shedding in the urine, with host 
infection occurring by the oral, respiratory and subcutaneous routes. In healthy monkeys, SV40 
appears to cause a low level persistent infection in the kidney, this demonstrates that SV40 is a 
nephrotropic virus (14). In immune compromised monkeys with Simian Immunodeficiency Virus 
(SIV), SV40 is associated with widespread infection, with the virus being detected in the brain, 
lung, kidney, lymph node, spleen and peripheral blood, suggesting SV40 may also have neurotropic 
and lymphotropic properties (15,16).   Polyomaviruses are also present in the human host. BK virus 
(BKV) and JC virus (JCV) are exclusive human viruses and were both discovered in 1971 (17,18).  
 
Recently, three new human polyomaviruses have been discovered (Table1, 12); KI virus (KIV), 
WU virus (WUV) and Merkel cell virus (MCV). The novel polyomaviruses KN and WUV have 
been established in respiratory fluids in individuals with respiratory infection and MCV is 
associated with Merkel Cell Carcinoma, a rare but aggressive human cancer of neuroendocrine 
origin (13,19,20, ). Phylogenetically, MCV is the only human polyomavirus that does not belong to 
the SV40 subgroup (21). This most recently discovered member of the Polyomaviridae has been 
shown to have the highest homology to the mouse polyomavirus subgroup and is most closely 
related to the lymphotropic polyomavirus (LPV, African green monkey polyomavirus), presumed to 
be of simian origin. While the polyomaviruses are thought to be highly species-specific and are 
believed to evolve in close association with their host, the close evolutionary relationship of MCV 
to LPV and SV40 to BKV and JCV calls this concept into question and may indicate the possibility 
that host switching can occur (21).  
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                                                                                                            (12) 
 
 
1.3:   SV40 infection in humans 
SV40 infection in the human host was seen as a rare event and only restricted to people living in 
contacts with the natural hosts-monkeys such as inhabitants of Indian villages located close to the 
jungles and workers attending to monkeys in zoos and animal facilities. Its association with the 
human host dates back to the 1950s and 1960s when SV40 contaminated vaccines occurred due to 
the ability of the virus to survive the formalin treatment used to inactivate the poliovirus (22). 
Human populations were exposed to SV40 by contaminated vaccines administered to hundreds of 
millions of people in United States, Europe Canada, Asia and Africa between the years of 1955-
1963 (9, 23). Additionally, it is thought that a major European manufacturer distributed SV40 
contaminated vaccines until as recently as 1978 (24).   
 
Soon it was shown that children vaccinated with contaminated oral polio vaccine (Sabin vaccine or 
OPV) shed  infectious SV40 in stools for at least 5 weeks after vaccination (25). Some children who 
received the same OPV, did not develop neutralizing antibodies even though they may have 
VIRUS NATURAL HOST YEAR OF DISCOVERY 
Murine polyomavirus Mouse 1953 
Murine pneumotropic virus Mouse 1953 
SV40 Monkey (rhesus macque) 1960 
SA12 Monkey (chacma baboon) 1963 
Rabbit polyomavirus Rabbit 1964 
Hamster polyomavirus Hamster 1968 
BK virus Human 1971 
JC virus Human 1971 
Bovine polyomavirus Cattle 1974 
Lymphotropic papovavirus Monkey (African green monkey) 1979 
Avian polyomavirus Bird 1981 
Rat polyomavirus Rat 1984 
Baboon polyomavirus type 2 Baboon 1989 
Cynomolgus polyomavirus Monkey (cynomolgus) 1999 
Goose hemorrhagic polyomavirus Goose 2000 
Chimpanzee polyomavirus Chimpanzee 2005 
Crow polyomavirus Bird (crow) 2006 
Finch polyomavirus Bird (finch) 2006 
KT polyomavirus Human 2007 
WU polyomavirus Human 2007 
Squirrel monkey  polyomavirus Monkey (Squirrel monkey) 2008 
MC polyomavirus Human 2008 
Table 1.1 Members of the polyiomaviridae family 
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 received large doses of live SV40 compared with the potential inactivated SV40 in inactivated polio 
vaccine (Salk vaccine or IPV). Additionally, SV40 human contamination occurred in experimental 
infection with live respiratory syncytial virus to adult volunteers and a neutralizing antibody 
response in about two thirds of the volunteers was revealed. Inactivated vaccines against 
adenoviruses and hepatitis A virus contributed to human exposure to SV40, even though, the 
amount of SV40 infections was almost certainly lower than that administered with OPV or live 
respiratory syncytial virus (26, 27, 28).  
 
The discovery of SV40 contaminated vaccine raised concerns and prompted research into the 
potential risk to human health. Soon after the identification of SV40 as a polio vaccine contaminant, 
several studies with hamsters started observing its generation of tumours in experimental animals. It 
was discovered that subcutaneous injection of  rhesus monkey kidney cell extracts into newborn 
hamsters led to the formation of sarcomas at the site of inoculation (29). Afterwards, it was 
observed that intracranial injection of SV40 into hamsters induce ependymonas, a type of brain 
cancer (30). The Syrian golden hamster has been developed as an animal model for SV40-induced 
tumours with primary brain cancers, malignant mesotheliomas (31), bone tumours (32a) and 
systemic lymphomas (32b), developing in a manner depending on route of SV40 inoculation. 
 
Furthermore, early serologic studies reported the presence of SV40 neutralizing antibodies at 
different titers, in the population that received IPV. Immune response appeared to correlate with the 
amount of SV40 present in the vaccine; 30-50% of individuals reached a significant antibody 
response against formalin-inactivated SV40 after three doses of the vaccine. Antibody titers 
persisted for a period of up to 3 years post inoculation. Additional serologic studies reported  SV40 
seropositivity in individuals with no history of immunization with contaminated IPV or other 
possible routes of SV40 infection. Studies such as Shah et al, detected antibodies to SV40 in adults 
and children born 1954 and after 1964 respectively, when IPV was free of SV40. This suggests that, 
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 there is the possibility of human infection by SV40 irrespective of initial exposure to contaminated 
polio vaccine and that SV40 is being transmitted in the population to this day (1, 4,  33, 34).  
 
To date, the route of transmission and prevalence of SV40 infection in human is still largely 
unknown. Serological studies have yet to provide comprehensive SV40 prevalence data. 
Nevertheless, recent studies with PCR and serological techniques indicate that SV0 infection occurs 
both in children and adults since SV40 DNA sequences was detected in normal and neoplatic 
tissues of people too young (1-30 years) or too old (60-80 years) to have been vaccinated with 
SV40-contaminated anti-polio vaccine. This finding may explain the lack of difference in cancer 
incidence between individuals vaccinated with SV40-contaminated and SV40-free anti-polio 
vaccines. Secondly, SV40 sequences and Tag were detected in blood and sperm specimens from 
normal individuals, oncological patients and in lymphoblastoid cells, which suggests that  human 
PBMCs may represent a reservoir and vehicle of SV40 spreading in the tissues of the host and 
among individuals. Thirdly, detection of SV40 sequences in urine and stool samples from both 
children and adults indicates the possibility of haematic, sexual and or fecal routes of transmission, 
which are likely to be responsible for SV40 horizontal infection in humans. Furthermore, there has 
been detection of specific antibodies to SV40 capsid antigens in human sera, though, there was no 
comparative data on SV40 DNA prevalence in PBMC and antibodies presence to SV40 antigens in 
sera from the same patients (35). 
 
Significantly, following laboratory experiments using hamsters, SV40 was shown to transform 
many human cell types in culture (36). In 1964, an interesting albeit unethical study by Jensen et 
a1., demonstrated that SV40-transformed human cells were able to produce subcutaneous tumours 
when injected into human volunteers (37). These SV40 transformed human cells grew as 
subcutaneous nodules for two weeks and then regressed, possibly because of an immune response. 
These early studies of SV40-mediated tumour induction in animal models indicated that SV40 was 
a potent cancer-causing virus and fuelled concerns about the exposure of the human population to 
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 the SV40 in contaminated polio vaccines. SV40 has since been detected in various human tissues, 
both normal and malignant (11, 38, 39, 40). 
 
Presently, the association between SV40 and human cancer remains very controversial. The 
discovery of the new human polyomavirus, MCV, integrated into merkel cell tumours, and the 
continuing studies on the cancer association of BKV and JCV, adds weight to the association of this 
family of viruses with human cancer. 
 
Comparism of  SV40, BKV and JCV 
BKV and JCV are exclusive human pathogens and were both discovered in 1971 (17, 18). BKV and 
JCV infection is widespread in humans and usually occurs in childhood. Seropositivity for BKV 
reaches 90% in children aged five to nine, with JCV seropositivity at 50 to 60% by the age of ten 
(41). BKV infection usually occurs at an earlier age than JCV (42). 
 
JCV and BKV share 69% sequence homology with SV40. The greatest homology is found in the 
early region coding for Tag and tags, whereas a lower homology is detected in the regulatory 
region. SV40 is phylogenetically closely related to JCV and BKV. They also evidence similarity 
with respect to size (5.2 Kb), genome organization and DNA sequence. The Tags of SV40, BKV 
and JCV strongly cross-react with the same antisera, while a less strong cross-reactivity is observed 
in most structural antigenic determinants of the viral proteins, named VP1, 2 and 3. The DNA 
sequences of SV40 share 70% homology with BKV, and 69% with JCV (41, 42). 
 
BKV was first isolated from the urine of a renal transplant patient with ureteric stenosis (17). 
Although the virus is ubiquitous, it does not cause disease in the healthy host, but can produce 
pathological effects in immunocompromised individuals such as renal transplant recipients, in 
whom it can affect as many as five percent (43, 44). JCV was first isolated from the brain tissue of a 
patient with progressive multifocal leukoencephalopathy (PML) (18), a demyelinating disease of 
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 the central nervous system caused by a lytic infection of oligodendrocytes (42). Similar to BKV, 
JCV is also associated with disease in the immunocompromised host, with PML usually only 
developing in individuals with a severely compromised immune system. PML was rare before the 
emergence of Human Immunodeficiency Virus (HIV) but this disease now  affects about 5% of 
HIV-infected patients and is considered to be an Acquired Immunodeficiency Syndrome-defining 
disease (45).  
 
 
1.4:   SV40 Structure and Genome 
SV40 is a non enveloped DNA tumour virus . The virion is about 45 nm, an icosahedral particle, 
with a density of 1.34–1.35 g/cm3. The viral genome is a circular, double-stranded DNA molecule 
of 5,243 bp in length in the reference strain SV40-776, with slight nucleotide variations in           
other strains, subdivided into three functional  domains (34). On a genomic level SV40 is closely 
related to BKV and JCV, sharing approximately 70% homology (11). Although these three viruses 
are closely related, they can be distinguished at the DNA and protein levels and also serologically 
by  neutralisation and haemagglutination inhibition assays (14). The genomic organisation of SV40, 
BKV and JCV is conserved with the genomes divided into three functional domains: the early 
region, the late region, and the regulatory region (46, 47, 48). The early genes are transcribed from 
one strand of the genome and the late genes are transcribed in the opposite direction from the 
complementary strand (42). The SV40 early viral coding regions (figure 1) comprises; the large T-
antigen (Tag), small t-antigen (tag) and the 17kT (tiny T antigen). On the other hand, the late 
region encodes the structural proteins VP1, VP2 and VP3 and a small regulatory protein called 
agnoprotein, sometimes referred to as VPx (49). There is also, the pre-micro RNA (miRNA) in 
every mature virus (48). 
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1.4.1:  SV40 Late Genome Region  
 
The Capsid Proteins and Functions  
 
The atomic resolution of the SV40 capsid is formed from the VP1(40kD), the major capsid protein 
forming the pentameric capsomers that make up the surface of the virus particle, the identical  
minor capsids VP2 (39kD) and VP3 (27kD) (14). The VP1 capsomers along with the VP2/3 
complexes are then joined by the C terminal arms of VP1 to form the icosahedral capsid 
surrounding the minichromosome (Figure 1.3) and the four host-derived core histones [H2A, H2B, 
H3 and H4] (48, 50). 
 
Figure 1.1: simian virus 40 (SV40) genome, showing the Tag, tag and tiny T antigen (17kT) in 
the early region. In the late region of the viral genome, the capsid proteins VPl, VP2 and VP3 
are shown along with the regulatory protein, agnoprotein [agno] and a pre-microRNA (miRNA). 
The regulatory region (ori) contains sequences for the early and late promoter and the origin of 
replication (48).  
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SV40 Entrance into the Cell: 
 
The cell infection starts by the binding of the SV40 virus to a receptor identified as the major 
histocompatibility complex (MHC) which is present on the plasma membrane of the host cell (51). 
SV40 binding to the host cell is co-directed by the capsid and VP2 (Figure 1.4). Subsequently, the 
bound virus traverses the membrane and enters a caveola which are large, 70-100 nm diameter 
flask-shaped invaginations on the plasma membrane (52),  where after ~20mins, it is endocytosed 
and transported in caveolae-coated vesicles to the caveosome through an actin- and dynamin-
dependent process. Each 60-70 nm transported vesicle contains a single SV40 virion (52, 53). SV40 
particles tend to bud from the caveosome and traffic to the ER. From studies, the ER has been 
suggested to be the SV40 disassembling domain since by the aid of the ER-resident molecular 
chaperones, the genome and VP1 pentamers associated with VP2 and VP3 are liberated (51, 52, 
54). Further dissociation of the VP1 pentamers tend to release the bound VP2 and VP3. The VP2 
and VP3 are inserted into the ER through oligomarization to form a multimeric complex that aids in 
transporting the genome across the ER membrane. The VP2 and VP3 complex integrates in the 
contiguous nuclear and ER membrane to directly transport the genome into the nucleus. Intact 
SV40 has also been proposed to enter the nucleus through the nuclear pore complex (NPC). 
 
Figure 1.2:  SV40 minichromosomes revealing the structural capsid proteins 
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 However, the largest macromolecule the NPC has been shown to translocate measures 39 nm in 
diameter indicating that the NPC would exclude the entrance of the intact 50 nm SV40 capsid (55). 
Further  integration of the VP2 and VP3 complex away from the nuclear boundary transports the 
genome into the cytoplasm (Figure 1.4), where one of the structural protein, ―VPX‖ utilizes its 
nuclear localization sequence and DNA-binding domains to traffic the genome into the nucleus 
(56). 
 
However, uncoating of the viral capsid must occur before the genome can be translocated to the 
nucleoplasm for replication. Polyomavirus capsid undergoes endocytosis and is transported to the 
nucleus where the viral DNA is uncoated and transcription of the early region begins. The nuclear 
envelope poses a significant barrier to viral infection and the trafficking of viral components. The 
strict size limit for nuclear entry requires large viral capsids to undergo uncoating, unwinding or 
nucleic acid release prior to nuclear entry (55, 57, 58). Enveloped virions (influenza, retroviruses, 
calciviruses, flaviviruses and herpesviruses) are also subjected to these constraints, as their lipid 
envelopes are shed exposing the capsids, which must then release the replication competent 
genome. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: model for SV40 Entry and Penetration of the ER Membrane (56.) 
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 Thus, capsids are exposed to cellular proteins that may be commanded by viruses to induce capsid 
uncoating or deformation to support nucleic acid release enabling genome delivery and replication.         
The nonenveloped dsDNA adenovirus (60-90 nm) employs cellular processes where, molecular 
chaperones and a virally encoded internal protease (p23) to weaken its capsid, allowing the genome 
to be released and enter the nucleus (59). The  mechanism of uncoating is the most poorly 
understood stage in the life cycle of SV40 but the size of the SV40 capsid  with its genome  
comprising of dsDNA associated with histones, indicates that the virus requires extensive 
disassembly before the genome is imported into the nucleus. This suggests that release of the SV40 
genome would closely imitate adenovirus, requiring a cellular trigger for disassembly. Since SV40 
traffics to the ER during cell entry, the ER likely contains the cellular trigger that initiates viral 
uncoating (Figure 1.4). The ER provides an oxidizing and calcium rich environment, optimized for 
the maturation and quality control of secretory proteins. It houses a variety of molecular 
chaperones, foldases and proteases, which play central roles in these fundamental cellular processes 
(60). 
 
LT assists in the transition from viral DNA replication to the synthesis of the late transcripts ~30 hr 
post-infection. Two late viral transcripts are transcribed: a 16S RNA that is transported to the 
cytoplasm where it translates VP1; and a second 19S transcript, which encodes for VP2, VP3 and 
the agnoprotein. While VP1 is the central protein that forms the viral capsid, the roles and functions 
of VP2 and VP3 in the infection process are poorly defined. VP2 is myristylated on its amino 
terminal glycine residue (39, 60, 61). Deletion of the myristyl group in a mouse polyoma Py mutant 
strain resulted in a 20 fold decrease in virus infectivity due to an apparent defect at, or prior to virus 
uncoating (56, 61). In sharp contrast to these findings, deletion of the unique N-terminal portion of 
VP2, which contains the myristylated residue, has no effect on SV40 viability. 
 
Since viral assembly occurs within the nucleus, newly synthesized viral structural proteins are 
directed for nuclear import by their intrinsic NLS. During infection, complexes of VP1, VP2 and 
12 
 VP3 form in the cytosol and are transported into the nucleus for DNA binding and virion assembly. 
The low calcium concentration and reducing environment of the cytosol likely aids in the assembly 
of virions by inhibiting the generation of SV40 capsids prior to nuclear import. Once in the nucleus, 
VP2 and VP3 binding to the genome is proposed to facilitate SV40 assembly by forming a scaffold 
for VP1 capsomeres to assemble the capsid   ( 62). 
 
 
Viral lysis and Optimal Spreading 
Little is known about the process involved in the dissemination of SV40 and nonenveloped viruses 
from the cell in general. SV40 infection is thought to result in cell lysis or death through a necrotic 
pathway due to the cellular trauma that results from the infection (63). However, electron 
microscopy studies have shown that SV40 virions saturate the apical surface of polarized cells ~48 
hr post-infection, ~12-24 hr before cell permeabilization occurs (64). 
 
Observation of SV40 within large smooth membrane vesicles suggest that SV40 utilizes a novel 
exocytic pathway that involves an unknown sorting signal to reach the cell surface. This would 
advantageously position the virus for the initial infection of adjacent cells prior to cell 
permeabilization and support the more efficient dissemination of virus for infection of distant cell 
populations upon cell permeabilization. This two-step process would enable the initial infections to 
occur without alerting the immune system, which becomes aware of the virus upon cell    
permeabilization. The plasma membrane of host cells is unquestionably compromised during 
infection. However, how this permeabilization is initiated is unclear (56, 60).  Several enveloped 
and non enveloped viruses utilize proteins termed viroporins or virus porins to mediate membrane 
disruption during viral entry and release.  
 
VP4 (Figure 1.5)  is a recently described protein and its expression is thought to coincide with viral 
lysis. VP4 expression is thought to represent a mechanism by which SV40 regulates its life cycle to 
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 enable optimal spreading of the virus (60). The nonenveloped poliovirus VP1 and VP4 proteins also 
aid in the delivery of viral RNA to the host. The poliovirus 2B protein has been proposed to initiate 
cell lysis. The 2B and myristylated VP4 proteins are small viral core components and VP1 contains 
an N-terminal α-helical domain that is also sequestered in the viral core. Upon receptor binding, the 
capsid undergoes a conformational change enabling VP1 and VP4 to insert into the host cell 
membrane and facilitate the transport of the viral RNA (65). A single point mutant in VP4 renders 
the channel ineffective, preventing the release of the viral RNA into the cytosol of the host   (65). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: proposed mechanism by which SV40 regulates its life cycle A-C, formation of 
pentamers for newly synthesized VP2 and VP3 by initially synthesized VP1, D-E, assembly of virion 
and five VP1 for VP2/3 so as to prevent them from integrating. Subsequently, VP4 is synthesized (F) 
and it oligomerises with VP3, possibly VP2 as well, then aims to the host cell (G) membrane so as to 
form a pore that initiates the lytic death of the host cell to release the progeny (Daniels et al., 2007).    
14 
 1.4.2:    SV40 Early Genome Region 
 
The Large Tag 
 
With the help of Tag and tag SV40 picks the lock on pivotal-check points in its life cycle control 
and achieves the transformation of host cells by expressing these two important proteins (Tag and 
tag) upon infection. This causes the cell to undergo an unrestrained proliferation circle that 
replicates and produces viral DNA and viral particles respectively. 
 
The large tumour antigen (Tag) of SV40 is a 708 amino acid protein that has many functions. It is 
the major transforming protein of the virus. T-ag is required for initiation of viral DNA synthesis 
and stimulates host cells to enter S phase. The oncogenic capacity of SV40 stems largely from the 
ability of this oncoprotein to bind to and inactivate the cellular tumour suppressor proteins  and cell 
cycle regulatory proteins that include the retinoblastoma proteins such as pRB, p107 and 
p130/pRB2. The tumour suppressor proteins  include  p53 and the transcriptional co activators p300 
and CBP (23, 66). Tag protein is found predominantly in the nuclei of SV40-infected and/or 
transformed cells (4). 
 
Tag Transformation Domains 
SV40 Tag is a multifunctional oncoprotein that possesses several defined functional domains that 
play a critical role in cell transformation and tumour induction (14). Figure 1.6 schematically 
illustrates different functional domains of SV40 large T antigen. The amino terminus of the Tag 
contains two distinct domains important in cell transformation. The far amino terminus of Tag 
includes the J domain involved in proper folding of protein complexes. This region shares 82 amino 
acid residues with small t antigen. The second region of the amino terminus of Tag mediates the 
binding to pRB and the pRB family members p107 and p130 (67). The J domains aslo coperate 
with LxCxE motif (residues 103-107) of the Tag to inactivate the functions of pRB family 
memebers and may also have additional transformation. The transforming ability of SV40 Tag is 
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 sometimes abolished by mutations that disrupt their binding with either pRB or p53 (68). 
Furthermore, the transforming potentials of SV40 Tag is contributed by its possession of additional 
features such as, the ATPase and DNA helicase. These features provide specifically binding and 
unwinding functions to SV40 Tag at its origin of replication, thereby assisting in the viral DNA 
replication. The DNA binding domain (131-259) is mainly known for  its function as a 
transcriptional transactivator. Tag, in addition to targeting cellular tumour suppressor proteins, also 
targets nuclear acetylases including CREB-binding protein (CBP), P/CAF and p300 (new family 
members of transcriptional co-activators). These regulatory proteins function as cofactors and play 
important roles in transcription and posttranslational modification of cellular tumour suppressor 
proteins (69, 70, 71). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: a schematic model representing the functional domains of SV40 Tag.  Nearly, 
minimal regions of T-antigen that retain binding activity to polymerase -primase (Pol), tumour 
suppressor proteins Rb and p53, human heat shock protein 70 (hsc70) and coactivators p300 and CBP 
are illustrated. DNA binding domain, ATPase activity domain, nuclear localization signal (NLS) 
domain, helicase domain, host range domain, Zn finger domain, and J domain are also depicted. 
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 Tag interacts with these proteins through multiple regions (Eckner et al, 1996; ) and inactivates their 
important cellular functions. This is also thought to contribute to deregulation of cell cycle 
progression. 
 
 
 
The SV40 Small T antigen (tag) 
 
Small t antigen of SV40, is a 174 amino acid protein (48) produced by alternative splicing of early 
transcripts. It shows an all -helix structure with two zinc-binding sites in the unique domain 
(figure 1.7). Small ag J domain comprises three helices with structure similar to large T antigen 
crystal structure and NMR structure of poliomavirus DnaJ-like domain (72, 73). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: A, The domains of Small tag (St) displaying the 174 amino acid with unique regions 
and the crystal structures similar to large T antigen and DnaJ-like domain. B, Small t  antigen 
contains a J domain adjacent to a zinc binding domain that directs the association of small t antigen 
with the trimeric  phosphatase pp2A.  SV40 small tag interacts with the B subunit-binding region of 
the PP2A A subunit, resulting in the displacement of the B subunits from the PP2A complex by the 
small t (72). 
 
 
  
 B 
A 
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 Small tag forms complexes with the regulatory subunit of the protein phosphate 2A (PP2A) family 
as in (Figure 1.7B) of serine-threonine phospatases (48, 74). This association appears to inhibit the 
function of PP2A, which in turn leads to more phosphorylated and increased kinase activity of 
several cellular kinases including MAP kinase and its kinase ERK, Jun N-terminal kinase (JNK) 
and a key ion transporter, the Na/H anti-porter (75, 76, 77).  
 
Tag assist solemnly on human cell transformation through its inactivation of the pRB and p53 
pathways. Studying the tag mutants has provided important clues to the function of tag during cell 
transformation. Mutations in tag that prevent the interaction with and inhibition of PP2A 
demonstrate that this interaction is required for tag mediated transformation. On the contrary, a tag 
mutant that contains only the PP2A inactivation domain (amino acids 88-174) retains the ability to 
reduce transformation, which suggest that the alterations in PP2A activity is required for the 
transforming activity of tag (78).   
  
Small tag in cell Proliferation and Transformation 
Studies have shown that tag expression results in enhanced proliferation rates which suggests its 
involvement in the promotion and regulation of cell cycle progression. It supports the modification 
from G1 to S phase in cell cycle; tag expression or suppression of PP2A B56g enhances the ability 
of cells to proliferate in low-nutrient  conditions (79, 80). Small tag also promotes the up-regulation 
of AP-1 transcriptional activity by regulating mitogen activated protein kinase (MAPK) through its 
over expression. Studies have observed the Raf, MEK1/2, ERK1/2 and KSR sites as possible spots 
MAPK regulation occurs. Additionally, expression of tag also gives rise to expression and elevation 
of certain proteins such as cyclin D1, B, thymidine kinase and dihydrofolate reductase linked with 
cell cycle progression (81).  Small tag activate other transcriptional factors such as cAMP 
regulatory element binding protein (CREB), SP-1 and E2F transactivation linked to cell cycle 
progression. Small t antigen can also regulate transcription by trans activating the Ad E2A 
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 promoter, which is transcribed by RNA polymerase II, and the Ad VA-I promoter, which is 
transcribed by RNA polymerase III (82). 
 
Furthermore, tag has been observed to stabilize c-Myc that is directly dephosphorylated by PP2A in 
tag transformation assays by inhibiting the activity of PP2A (Figure 1.8). A stabilized c-Myc 
mutant is also capable of substituting for tag expression (83, 84). SV40 tag has been also implicated 
in anti-apoptotic pathways (Figure 1.8) and induction of changes in cytoskeleton. Studies have 
shown lines of evidence implicating tag in regulation of apoptosis. Transcriptional analysis of 
human cells expressing tag revealed up-regulation of anti-apoptotic targets of NF-kB (Figure1.8) 
such as ALDHI, SERPINB2 and surviving. NF-kB is activated by tag regulation through protein 
kinase and phosphatidylinositol 3-kinase (P13K) signaling (85). It is also involved in the regulation 
of the P13K/Akt pathway. Genetic substitution experiments have demonstrated that under tag 
expression either activated PI3K or a combination of the activated PI3K effectors Akt and Rac1 
induce human cell transformation (Figure1.8). Equally, blocking PI3K function inhibits tag-
mediated transformation (86).  
  
 
 
Figure 1.7: cell transformation mediated by tag downstream expression leading to 
inhibition of PP2A complexes that activates numerous signaling pathways and 
regulation of c-Myc, Akt and Anti-apoptotic NF-kB pathways (74). 
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 SV40 tag expression also aims at PP2A-dependent processes governing the cytoskeleton. Over 
expression of tag in epithelial cells induce dramatic F-actin rearrangements with increase Racl-
induced membrane ruffling, Cdc42-initiated filopodia and loss of RhoA-dependent stress fibers 
(87). Studies on transcriptional profiling analyses have shown that a number of genes such as 
osteopontin, paxillin and gasoline involved in cellular adhesion and motility are up-regulated by the 
presence of tag. It also causes down regulation of several genes like Plakoglobin, claudin11, ICAM-
1 and VCAM-1 involved in cell-cell adhesion and junctional adhesion. This down regulation causes 
severe defects in formation and barrier properties of tight junction in cells with tag expression (88).   
 
 
1.4.3:    SV40 Regulatory region and Micro RNA 
 
The viral genome of SV40 shows a regulatory region consisting of DNA replication promoter and 
enhancer elements. A non-coding region, it however functions to orchestrate viral transcription and 
replication. Its characteristic series of specific nucleotide motifs serve as binding or interaction sites 
for proteins involved in transcription or DNA replication (91). 
 
The structure of the regulatory region of SV40 viruses can be distinguished in accordance with the  
number of enhancer elements observed. Hence, two types of regulatory region structure in the SV40 
viruses based on the presence of enhancer elements present. Strains having two 72-base pair 
enhancer elements are referred to as having a 'non-archetypal' or complex regulatory region 
structure while regulatory regions lacking a duplicated enhancer element are considered 'archetypal' or 
simple structures (89).  
 
In the case of the reference strain of SV40-776, variants containing one enhancer element are 
designated 776-1E (-1E virus) while viruses with a duplicated enhancer are called776-2E (-2E 
virus). These -2E viruses have been shown to replicate faster in tissue culture (89). It has been noted 
that while natural isolates of SV40 or virus isolated from human tumours generally do not contain 
enhancer duplicates, laboratory adapted monkey strains of SV40 usually contain two 72-base pair 
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 enhancer elements (90).  However, it is thought that a mixture of both archetypal and non 
archetypal regulatory regions may be present in monkey isolates and that laboratory tissue culture 
allows the selection of the faster growing variants (91).  
 
Studies have shown that the regulatory region of SV40 may exert a significant influence on tumour 
incidence. In studies on SV40 tumour induction in Syrian golden hamsters (Mesocricetus auratus), 
the -lE virus was found to induce tumours in a larger proportion of animals than the -2E virus (92). 
While the faster speed of viral replication has typically been seen as an advantage for a virus in 
overcoming the ability of the immune system to control its growth, it has been proposed that slower 
replicating viruses may evoke a weaker immune response and therefore enhance their likelihood of 
persistence by circumventing immune surveillance (93). Based on this theory, it is thought that the 
faster replicating SV40 -2E virus is recognized and cleared more efficiently by the host immune 
response than the slower replicating -lE virus which would be more likely to evade the immune 
system and persist (90).  
 
It has also been recently recognized that the viral regulatory region of SV40 may exert effects on 
vertical transmission in hamsters (94). In a study investigating SV40 transmission in the hamster 
model, it was found that hamsters inoculated with SV40 strains containing complex regulatory 
regions (-2E) transmitted virus more frequently than those infected with simple enhancer (-1E) 
viruses. Further studies are required to determine the relationship between the regulatory region and 
pathogenesis of SV40 infection, including the possibility that some SV40 strains or variants are 
more pathogenic than others. 
 
Micro RNA 
 
Since its discovery in the 1990s, relentless study efforts on micro RNA affirmd that SV40 encodes 
RNA that play important role in the viral life circle (48). Cellular and viral miRNAs are small 
regulatory RNAs that play critical role in gene regulation. (95). 
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 miRNAs function by binding to complementary sequences in the 3' un-translated regions of 
messenger RNA (mRNAs), and then mediating mRNA degradation or repressing translation, 
ultimately leading to reduced protein expression. It has been known for some time that some viral 
genomes include non-coding RNA such as miRNAs, but their function is only starting to come to 
light. In fact, recent studies suggest that viral miRNAs may function to evade the host innate 
immune response, regulate gene expression and possibly contribute to viral-mediated 
tumourigenesis ( 96, 97). Micro RNAs are useful to the virus in that they are non-immunogenic, 
take up a small amount of genomic space and are powerful regulators of gene expression (98).  
 
SV40 encodes a pre-miRNA, designated miR-S1, which is processed into two miRNAs that bind to 
the early RNAs, thereby directing their cleavage at a late stage of the viral cell cycle (98). The end 
result of the miRNA action in SV40 is a reduction in the expression of viral T antigens. It is known 
that some protein products of early SV40 genome, such as Tag, are very immunogenic and generate 
a strong cytotoxic lymphocyte (CTL) immune response. The function of the SV40 miRNA in down 
regulating expression of these immunogenic proteins suggests that the miRNA is involved in 
immune evasion strategies. Studies conducted using a mutant SV40 virus named 776-2E-SM, that 
lacks the viral miRNA, have shown that target cells infected with the mutant are more sensitive to 
CTL-mediated death than cells infected with a wild type SV40 (47).  
 
In addition, release of the cytokine interferon-y was also diminished when CTLs encountered cells 
infected with the wild type SV40. Together these results suggest that SV40 miRNA may play a role 
in evading the adaptive immune response (47). Viral miRNAs in the herpes viruses Epstein Barr 
virus (EBV), human cytomegalovirus (HCMV) and Kaposi's sarcoma herpes virus (KSHV), have 
been shown to function in modulating the virus life cycle and human immune response, thereby 
underlining the importance of miRNAs in viral infections (99). 
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 1.5:   Life Cycle of  SV40 in Host Cells 
 
SV40 cellular infection begins by its binding to the major histocompatibility complex class 1 (MHC 
class 1) which is present on the plasma membrane of the host cell (Figure 1). The MHC class 1 
molecule act as the specific cell surface receptor for SV40 (100, 101). The life cycle of SV40 in 
human cells is less well understood but the expression of MHC class I by nearly all nucleated cells 
thus explains the broad tropism of SV40 and its ability to infect and induce transformation in many 
types of cells and tissues (23). Not all cells expressing MHC class I are, however, susceptible to 
SV40 infection and differential ability in infecting polarized epithelial cells via the apical or 
basolateral surfaces have been reported, despite similar MHC expression on both membranes (42). 
This suggests the possibility of other factors contributing to SV40 tropism  such as co-receptors 
factors for viral entry after binding or additional transcription factors that may need to be present for 
viral replication to occur (102).   
 
In the natural monkey host, SV40 infection is known to result in a lytic infection. This viral 
production is controlled by the immune response and the virus thus persists in the kidney where it 
can be reactivated by immunosuppression (103). Further, after binding to the cell surface, the 
poliomavirus capsid is transported to the nucleus where uncoating and transcription of the viral 
DNA into early region of the genome occurs. The alternatively spliced transcription from the early 
region gives rise to two mRNAs that encode the large Tag and small tag. SV40 large Tag, a nuclear 
phosphoprotein of 94kD, is an essential factor for viral DNA replication. It binds to the viral origin 
of replication where it promotes unwinding of the DNA double helix and recruitment of cellular 
proteins that are required for DNA synthesis, including DNA  polymerase-a and replication protein 
A (39).  
 
SV40 depends on cellular enzymes and cofactors for DNA replication and these proteins are 
expressed in  S phase. Large T antigen modulate cellular signaling path ways to induce cells to enter 
S phase and is thought to stimulate the cell cycle through its ability to bind to numerous cellular 
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 proteins involved in crucial transduction path ways that control cell cycle progression and apoptosis 
(104). Small tag does not partake in lytic infection in culture rather assists the Large Tag in 
transformation of cells by SV40 and increases virus yield in permissive cells. In human cells, 
through binding to the cellular tumour suppressor proteins of the pRb family, Tag expression leads 
to the induction of S phase. pRb normally binds the transcription factor E2F to form a 
transcriptional repressor complex. However, on binding to SV40 Tag, a dissociation of E2F-pRb 
complexes occurs (106), releasing E2F to activate expression of growth stimulatory genes (Figure 
1.9 A). 
 
This pre-emptive signal for S phase induction and cell division and the resulting unbalanced DNA 
synthesis induces the cell to initiate a p53 response (tumour suppressor gene). p53 normally senses 
DNA damage and either pauses the cell cycle to repair the DNA or directs the cell to enter the 
apoptotic pathway, known as programmed cell death. However, Tag overcomes this obstacle by 
binding to p53 and inhibiting its function (Figure 1.9B). The cell is thus induced to proliferate and 
the p53-mediated checkpoint is abolished. This Tag-mediated subversion of cell cycle control 
allows cells with genetic damage to survive and enter S phase, leading to an accumulation of Tag-
expressing cells with genomic mutations that may promote tumour growth as an accidental side 
effect of the viral replication strategy (105, 106, 107). 
 
As SV40 virus replication proceeds, expression of the late genes begins. The gene products of the 
late region are the capsid proteins VP1, VP2, VP3, which assemble with the replicated viral DNA to 
form virions. In infection of the natural monkey host these virions are released upon cell lysis, 
resulting in death of the host cell (39). The life cycle of SV40 from infection to the production of 
new virions is thought to take 96 hours in permissive cells (Figure 1.5), resulting in about 300 
infectious progeny virions per cell (60, 108). 
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Although polyomaviruses grow most efficiently in the cells of their natural host species they do not 
display absolute host specificity (75). Several outcomes are observed in cellular infection by a 
polyomavirus. In the natural host, cells are permissive to viral infection and are able to support viral 
replication which results in lytic infection and viral progeny (103). In general, these infections are 
non-oncogenic for their natural hosts (109). However, SV40 and other turnour viruses may become 
 
Figure 1.8: interaction of SV40 Tag with pRb and p53 Schematic representation of the 
interaction of SV40 Tag with tumour suppressor proteins pRb and p53. (A) pRb normally binds 
transcription factor E2F, forming a transcriptional repressor complex in early GI phase of the cell 
cycle. Normally, when pRb is phosphorylated by cyclin-dependent kinases (cdk), E2F is released and 
activates growth-stirnulatory genes. Tag binding to pRb causes unscheduled dissociation of pRb-E2F 
complexes, releasing active E2F. (B) The function of p53 is to sense DNA damage and either cause 
the cell to pause in late GI phase for DNA repair or direct the cell to commit suicide through the 
apoptotic pathway if repair is not possible. p53 can transcriptionally induce p21, a cyclin-dependent 
kinase inhibitor, which blocks the activity of GI cyclin-cdk complexes arresting cell cycle progression 
in late GI phase. Binding of the SV40 Tag results in p53 being sequestered, abolishing its function 
and allowing cells with genetic damage to survive and enter S phase. As a result, Tag-expressing cells 
with genomic mutations accumulate that may promote tumourigenic growth (23). 
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 more oncogenic when they cross species (2, 4, 110). SV40 DNA can become integrated into the 
chromosomal DNA of the cell especially upon infection of the non-permissive cells. 
 
Different studies indicate that SV40 can replicate productively in human cells, including 
spongioblasts, fetal neural cells, new born kidney cells and some tumour cell lines, with poor 
growth outcome in human fibroblasts. Hence, the human cells are said to semi- permissive to SV40 
infection (36, 103, 110). Some human  cell types undergo visible cell lyses in response to SV40 
infection, whereas other cells fail to exhibit cytopathic changes and produce low virus levels. 
Studies have shown that while SV40 infection of human fibroblasts leads to a productive outcome 
with viral replication, the virus establishes a persistent, non-lytic infection in mesothelial cells (3) 
and becomes transformed at high rate (1000 times higher than that of human fibroblast) by SV40 
Tag alone, releasing infected virions due to persistent infection. Similar situation has also been 
observed in human lymphoblastoid B cell line where SV40 progeny is produced at a low level (38).   
 The behavior of SV40 in mesothelial cell is very uncommon for a DNA tumour virus. Studies have 
evidenced that DNA tumour viruses either infect permissive cell lines with the production of an 
infectious viral progeny or infect and transform non-permissive cells without a productive viral 
cycle. The rate-limiting step to sustained transformation is thought to be the random integration of 
viral DNA into the cellular genome by non-homologous recombination. If this integration occurs 
such that the early coding sequences are intact allowing Tag to be expressed, the host cell and its 
subsequent descendants are transformed (4, 38, 48). 
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Possible Cell Transformation Phases from Primary Cell Growth.   
Cell transformation could be described as the changes in types of proteins expressed and growth 
characteristics that take place in cells infected by some viruses, including tumour formation by 
retroviruses. Transformation could also be oncological or malignant (111,112). Investigating the 
process of the cell transformation induced by different agents in vitro can indisputably be a very 
powerful approach to elucidate this basic mechanism. Currently, this type of experiment has been 
carried out extensively with animal cell models, while only rarely has been observed with human 
cell types (113, 114). The difference in susceptibility and transformation between animal and human 
 
Figure1.9:  possible Outcomes of SV40 infection in different Cells. 
Left—In SV40 infection of non-permissive mouse cells, no production of viral particles and malignant 
transformation can occur. Middle—Infection of permissive monkey cells with cell lysis that results in 
the production of progeny or many viral particles. Right—Infection of human mesothelial cells that 
leads to very limited production of viral particles with limited cell lysis and frequent malignant 
transformation (110). 
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 cell models has been attributed to DNA repair capacity, response to oxidative stress, epigenetic 
factors such as DNA methylation (114).  
 
 
 
 
 
 
 
 
 
 
 
 
In cell transformation, three stages/phases are observed (Figure 1.11): (a) production of cells with 
an extended life (EL. Cells) from primary diploid cultures that is characterized mainly of diploid 
primary cells in pre-crisis stage; (b) emergence of immortalized cells (I. Cells) from EL cells after 
passing through stage two crisis or post crisis stage; (c) development of tumourigenic cells (T. 
Cells) from EL or I cells in stressful cultural conditions (64, 115, ).  
Furthermore, transformation and postponement of senescence of cells can be carried out in human 
cells such as lymphocytes (with short life span in culture) using different experimental approaches 
such as transforming by tumour viruses (Herpesvirus saimiri, infection with T-cell leukemia virus-
 
Figure 1.10: schematic presentation of the three most frequently cited cell transformation 
Stages/Phases with their characteristics. Phase 1 showing Extended life cells (EL) originated from 
the primary cells followed by Phase 2- the Immortalized cells (I) and in stressful cultural conditions 
tumourigenic cells –Phase 3 is developed from I and EL cells. 
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 type1, transfection with Extein-Barrvirus, EBV), or with viral oncogens such as the large T antigen 
(Tag) of different Polyomaviruses (116a, 116b). Previously, the transforming capacity of the Tag 
has been demonstrated in human lymphocytes in vitro (38, 117, 118).  
 
1.6:   The Immune Response to SV40 
Usually, the viral replication cycle begins with the binding of the virus to the host cell through 
specific receptors (adsorption). For SV40, the host cell receptor is the MHC class 1 and it 
determines the tropism and specifity of SV40 virions. The effector in the cellular immune response 
to virus is the CD8
+
 cytotoxic T lymphocyte (CTL), which lyses virus-infected cells following 
recognition of virus encoded epitopes presented on the cell surface by MHC class 1. several factor  
like the proper  generation of the virus epitopes, successful loading and stable binding of virus 
epitopes to  MHC class 1 molecules, proper trafficking of the complex to the cell surface and the 
presence of T cell in the repertoire capable of recognizing the virus epitopes  contribute to 
successful CD8
+ 
T-cell recognition of virus epitopes (120). The MHC class 1 molecules comprises 
of a trans-membrane heavy chain that associate non-covalently with β2 microglobulin and a bound 
peptide representing the T cell recognized epitope. The epitope recognized by CD8
+  
T cells are 
typically peptides of 8-10 amino acids in length that can be derived from a variety of virus proteins.
  
This length requirement is imposed by the structure of the peptide binding groove in which the 
closed ends of the groove accommodate the amino and carboxyl termini of the peptide. 
 
Entry of virus proteins into the MHC class 1 antigen presentation pathway might occur through 
either direct infection of APCs or by ―cross-presentation‖ in which virus-infected cells or cellular 
debris are phagocytosed,  and the antigens are shuttled into the MHC class 1 processing pathway. 
Recently,  it has been observed that CD4
+
 T cells prime APCs via signaling through the CD40/ 
CD40 ligand receptor pair.  These activated APCs are then capable of delivering co-stimulatory 
signals via B7-CD28 or similar engagements for the activation of naïve CD8
+ 
T cells (119). 
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Studies addressing the requirement for CD4
+ 
T cells help for successful priming of virus-specific 
CD8
+
 T-cells responses have suggested that some virus-specific responses are independent of CD4
+
 
T-cell help, perhaps, due to alternate mechanisms for activation of APCs (119, 120). 
 
SV40 Cellular Immune Response During Viral Lytic Cycle  
Adaptive and innate immunity are firmly involved in defense against viral infections. However, 
nature of virus-host interaction determines the participation of the various arms of the immune 
response. Virus neutralization antibodies play a definitive role in interrupting viral spread while the 
T lymphocyte-mediated mechanism are involved in the elimination of virus-infected target cells. 
The CD8
+ 
T lymphocyte (CTL)  is responsible for this effect and it lyses virus infected cells by 
recognizing a viral epitope presented by the MHC class 1 antigens. In a typical immune response to 
viral infection, natural killer cells that recognize virus-infected cells are recruited followed by a 
burst of CTL after about 4-7 days. The CTL tends to fall to base line as the virus load declines and 
then persist as memory T cells which can be recalled upon re-exposure to the viral gene products. 
The mechanism of CTL effector is very essential for the elimination of virus- infected cells, 
specifically mainly on those viruses that cause persistent infections (121). 
 
Furthermore, the CD4-mediated T-cells responses are involved in helping B cells produce 
antibodies and cytokines involved in the proliferation of CD8
+ 
T cells and activation of APC. In 
human poliomaviruses, only SV40 has an available, reliable model which is the rehesus monkey 
and as its natural host. For BKV and JCV no animal models in which virus infection leads to its 
replication in vivo. This particular reason is affecting tremendously the study of T-cell mediated 
immunity during infection of natural hosts. Recently, a study have reported on the role of CD8
+
 T 
cells in interrupting the infectious cycle infection in SV40 in vitro. In this study, the murine CTL 
clone specific for H2-K
b
 and H2-D
b
 were utilized along with restricted SV40 T antigen epitopes as 
probes for abrogating the SV40 infectious cycle in permissive monkey cells. To utilize the strategy, 
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 a continuous line of monkey kidney cells, TC-7, was transfected with murine H2-K
b
 and H2-D
b
 
class 1 antigens, thus allowing the presentation of T-antigen epitopes to SV40 T-antigen-specific 
CTL clones generated by B6 mice. From this study, it was observed that, the interaction of T-
antigen-specific CTL clones with SV40 infected TC7/H-2D
b
 or TC7/H-2K
b
 cells for 5hrs reduced 
the SV40 yield by 70-90% as measured by the infectious center assay. This result suggests that: (a) 
the target of CTL is a non virion protein T antigen, which is synthesized before viral DNA 
replication; and (b) the CTL mediated events may also take place in the natural host undergoing 
SV40 infection (122, 123). 
 
 
 1.7:    SV40 Association with Human Cancers 
 
It has really been established that SV40 is a potent transforming virus, having observed its 
induction/generation of tumours in experimental animal models and various types of cells in vitro. 
More recent evidence from serological and molecular studies revealing its presence in humans raise 
the possibility that the virus could have transforming capabilities in human cells both in vivo and in 
vitro. 
 
SV40 in Human  Brain Tumours 
Detection of SV40 DNA sequences in early studies was in rare cases due to low sensitivity used 
techniques. However, the studies supported previous findings of SV40 induction of brain tumours 
in hamsters (124). Recently, improved polymerase chain reaction methods (PCR) as amplification 
based methods has shown breakthrough in SV40 research, providing a sensitive method of DNA 
detection in human samples. PCR has been used to detect SV40 sequences in a variety of child hood 
brain tumours such as  ependymoma and choroid plexus tumours, as well as thyroid, pituitary and 
parotid gland tumours. These human brain tumours correspond to the neoplasms that are induced by 
SV40 experimental inoculation in rodents or by generation of transgenic mice with the SV40 early 
region gene directed by its own early promoter-enhancer (39, 125).   
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There has been numerous studies with continuing reports of SV40 detection in brain tumours (90). 
Not only has the virus been detected but SV40 Tag has also been found complexed with tumour 
suppressors p53 and pRb in brain tumours, providing further evidence of a direct functional role for 
the virus in tumourigenesis (126). In addition to patient studies, an interesting report was published 
detailing the development of a meningioma in a laboratory scientist who had worked with an SV40-
transformed cell line (127). This brain tumour was found to contain SV40 DNA sequences 
indistinguishable from the laboratory virus, suggesting that laboratory-acquired SV40 infection may 
have been responsible for turmour development. A meta-analysis of the association of SV40 with 
brain turmours revealed that samples from patients with brain tumours were almost four times more 
likely to have evidence of SV40 infection than those from controls (90). Furthermore, SV40 has 
been detected in multiple histological types of brain tumour, in both children and adults. Indeed, 
since brain tumours represent 21% of all cancers in children, it has been hypothesised that this high 
incidence of paediatric brain tumours may suggest acquisition of an infectious agent such as SV40 
from the mother (90).  However, other studies examining polyomaviruses in brain cancers using 
primers capable of detecting SV40 sequences have not reported co-infection (128). 
 
 
SV40 in Malignant Mesothelioma  
Malignant mesothelioma is an aggressive tumour of the lung pleura, pericardium or peritoneum, 
with mean patient survival of only one year from time of diagnosis (129). Mesothelioma has been 
firmly linked to asbestos exposure. However, since10-20% of occurrence is in people with no 
known exposure and only 5-10% of those exposed to high levels of asbestos develop this type of 
cancer, it is thought other factors may be involved in mesothelioma development (3). Asbestos and 
SV40 have been shown to be co-carcinogens, with SV40 infection lowering the amount of asbestos 
required for malignant mesothelioma to develop in hamsters. This raises the possibility that SV40 
may act as a co-factor in other cancer types (130). 
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Recent studies have shown that SV40 sequences could be found in up to 60 % of mesotheliomas  
and that 100 % of the infected cells express SV40 T antigen (Tag). However, the infected cells are 
not lysed by SV40 due to abnormally high levels of p53 expression in mesothelial cells which binds 
Tag; and with SV40 there is a possibility of acquisition of genetic mutations and a malignant 
phenotype (40, 129, 131, 132).  
 
Interestingly, the paracrine mechanism, exerted by the SV40 Tag in murine and canine cells has 
been also observed in human mesothelial cells. In these mesothelial cells, SV40 Tag activates an 
autocrine/paracrine loop, involving the hepatocyte growth factor (HGF) and its cellular receptor, 
which is the product of the oncogenes c-met, as well as the vascular endothelial growth factor 
(VEGF) and its cellular receptor VEGFR. HGF and VEGF released from SV40-positive human 
cells, bind their receptors in neighboring and distant SV40-positive and SV40-negative cells, 
driving them into proliferation and tumourigenesis. In this human cell models only one cell out of 
100/1000 cells needs to express the Tag to transform all the cells of the monolayer (133, 134). 
 
Numerous possible roles of SV40 in the pathogenesis of human mesothelioma has been observed: 
(a) SV40 ability to bind in vivo p53 and RB family proteins in human mesothelioma samples;  (b) 
its activation of Notch-1, a gene promoting cell cycle progression and cell proliferation in primary 
mesothelial cells; (c) induction of apoptosis in mesothelioma cells transfected with antisense DNA 
to the SV40 early region genes; (d) presence of SV40 tag-specific cytotoxic T lymphocytes in sera 
of patients affected by mesothelioma; (e) finally, poorer prognosis of mesotheliomas harboring 
SV40 early region sequences compared to SV40-negative mesotheliomas. In fact, mesothelial cells 
are specifically susceptible to infection and transformation by SV40. Some studies give emphasis 
on the fact that SV40 tumour antigens induce telomerase activity in human mesothelial cells 
without any effect in fibroblast cells. This suggest that, both SV40 oncoproteins specifically 
participate in the immortalization of mesothelial cells during mesothelioma development (135, 
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 136). The association between SV40 and malignant mesothelioma appears to be the strongest for 
any SV40-associated cancer (124). Nevertheless, studies such as James et al., have failed to detect 
SV40 sequences from 43, 30, 17, and 19 mesothelioma cases from Johannesburg-South Africa, 
Wales-United kingdom, New York and Croatia respectively (137). 
 
  SV40 in Non-Malignant Specimens 
Previous studies have shown expression of SV40 Tag in certain cancers suggesting the possibility 
of SV40 etiologic role support in these cancers. Observation of animals with tumours developed 
antibody against SV40 Tag and neutralization of SV40 with specific antibody before virus 
inoculation prevented cancer development (32b, 138). Probably, all these findings in experimental 
models prompted past as well as recent investigators to consider the role of SV40 infections in some 
human malignances and non-malignances as well.  
 
Studies have reported the localization of SV40 DNA sequences to renal tubular epithelial cell nuclei 
in renal biopsies of patients with focal segmental glomerulosclerosis  using  in situ hybridization. In 
these studies, several strains of SV40 were displayed, these strains included SV40 strain 776 and 
other strains with mutations in the early and late regions (39, 138). Additionally, other different 
studies showed that SV40 DNA sequences from the viral regulatory region were detected and  
identified  in the allograft of  immune-compromised pediatric renal transplant recipients and in the 
native kidneys of a young adult lung transplant patient with polyomavirus nephropathy (139). 
Another study, reported that SV40 and BKV sequences have been co-detected in the kidneys of 
patients with post-transplantation intestinal nephritis thus suggesting that SV40 may co-operate in 
the etiopathogenesis of this chronic  disease. SV40 sequences was also detected in kidney tissues 
and urine. Furthermore, SV40 DNA sequences in PBMCs in both oncological patients and normal 
individuals from various population  have also been detected by different study groups (39, 40, 
176). These results demonstrate the nephrotropic and lymphotropic properties of SV40 and indicate 
that the kidney and PBMCs can serve as  reservoirs for the virus in humans. Generally, it appears 
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 that patient with acquired and or iatrogenic immunosuppression seems to be at risk for SV40. 
Although, the frequency, natural history and morbidity of the virus in this increasing patient 
population are not clear ( 125). 
 
 
 
1.8:   Association of  SV40  with  Lymphomagenesis/Non-Hodgkin’s  Lymphoma     
       (NHL) 
 
Studies have shown that  the types of tumour developed/induced by SV40 in hamsters are in the 
same range with human tumour with SV40 DNA sequences. Since the past decades, the role of 
SV40 in lymphomagenesis has been investigated in humans, although, lymphomagenic potential of 
SV40 has long been established by different studies in experimental animals. Diamandopoulos has 
shown that, 72% hamsters inoculated with SV40 intravenously developed lymphomas while the 
control- in-inoculated group no lymphoma result (32b). The histological type of resulting tumours 
was very consistent with diffuse large cells and the lymphoma was shown to be B-cell origin with 
cell surface antigen (140).  
 
Past studies observed that lymphomas were one of the most common malignancies induced by 
SV40 in experimental  models (141). Knowledge of  these animal model studies prompted the 
investigation of the possible role of SV40 in human lymphomagenesis. There has been continuous 
detection of SV40 along with other polyomaviruses BKV, JVC and MCPyV in healthy blood 
donors and in B cell rich tonsillar tissues of immunocompetent children (40a,  40b, 94, 142, ). This 
suggests the possibility of SV40 having a tropism for the lymphatic system, which is a very 
important factor to use in trafficking the virus around the body and in pathogens. 
 
Recently, in United States, Lymphoma has been identified as the most common type of blood 
cancer, the seventh most common cancer in adults and the third most common in children. In the 
United States and European Union, about 54,000 and 50,000 people are diagnosed annually with 
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 non-Hodgkin lymphoma (NHL) respectively (http://www.cdc.gov/vaccinesafety/updates/archive/polio...). 
There has also been a dramatic increase in NHL incidence in the last 30 years, with an 80% increase 
in the US noted between 1973 and 1997 (143). 
 
NHL includes a group of more than 20 different lymphoproliferative disorders arising from 
Lymphocyte cells [B, T, and NK cells] (144).  Significant association of SV40  has been established 
by several studies from the continuous detection of SV40 DNA sequences (Table 1.2). Despite the 
fact that  the exact etiology of NHL is not known, but as EBV is associated to Burkitt’s Lymphoma, 
KSHV associated to primary effusion lymphoma and human T lymphotropic virus type 1 (HTLV-
1), adult T cell known to be associated to leukemia/lymphoma—similarly,  some infectious agents 
have been identified to cause NHL by lymphocyte infection. Virus such as hepatitis C has also been 
implicated as an increasing risk factor of NHL through chronic immune stimulation in a chronic 
infection (145).  
 
Immunodeficiency is also considered a major risk factor for the development of NHL, and it is a 
common malignancy in HIV-infected patients as a result of deficient immunosurveillance of 
oncogenic viruses (146, 176). Additionally, immunosuppressed patients in other poliomavirus 
related diseases such as BKV and JVC  have also shown to be at risk of NHL. This data suggest that 
SV40 positive NHL does not appear to be dependent of pronounced immunodeficiency in the host 
(11). 
 
Numerous significant reports have identified SV40 DNA sequences in diffuse large B cells 
lymphoma and follicular lymphoma, two of the most common histologic types of B cell lymphoma 
accounting for approximately 50-60% of all cases of NHL (23). Involving SV40 sequences in these 
particular types of NHL raises the question about the significance of the developmental stage of B 
cells in the progression to lymphoma and indicates mature B cells to be  more susceptible than 
precursor cells in the transforming potential of SV40. 
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Table 1.2: detection of SV40 DNA sequences in human lymphoploriferative disorders/NHL 
Study Sample Technique Used Country 
SV40 DNA in 
Lymphoproliferative 
disorder/NHL 
No Positive/no.tested (%) 
 
 
Martini et al., 1998b 
 
 
Human  lymphoproliferative disorders 
obtained from human-
immunodeficiency-virus (HIV)- 
seronegative and HIV-infected patient 
PCR,  Filter hybridization 
and immunochemistry 
 
 
 
Italy 
 
 
Shivapurkah et al.,  
2002 
 
68 Non Hodgkin Lymphoma and 31 
Hodgkin Lymphoma  patients 
PCR and Southern blot 
 
USA 
 
 
MacKenzie et al., 
2003 
 
152 NHL samples, from patients in the 
U.K. with lymphadenopathy and 
lymphoid leukemia   
PCR assay UK 0/152 (0) 
Nakatsuka et al., 
2003 
122 cases with HNL 
Immunohistochemistry, 
PCR, Southern blot and in 
situ Hybridization 
Japan 
 
14/122(11) 
 
Engels et al., 2004 
724 incident NHL case patents and 
622 control subjects from a population 
based U.S. case control study 
Enzyme immunoassays USA 
 
52/724 (7.2) 
 
 
Butel et al., 2003 
154 NHL patients, 186 non-malignant 
lymphoid samples and NHL from 
HIV-I-positive patients 
PCR,  
Southern blot, 
Hybridization analyses 
USA 
 
64/154 (42) 
0/186 (0) 
33% of NHL from HIV-
l-positive patients 
Dana et al., 2005 119 B cell NHL main samples Elisa, logistic regression USA 
24/119 (16.8) 
33/184 (15.2) 
 
Meneses et al., 2005 
125 Lymphoma and control specimens 
from HIV negative patients 
PCR, Southern blot and 
immunohistochemistry 
Costa Rica 
 
30/125 (24) 
0% from Control 
Samples 
 
Po-Min Chen et al., 
2006 
19 frozen lymph nodes from NHL 
patients 
PCR,  
Southern blot, 
hybridization analysis 
Taiwan 
13/91 (14.3) 
 
Amara et al., 2007 
108 diffuse large B-cell  type 
lymphoma (DLBCL) samples 
PCR assays Tunisia 
 
63/108 (56) 
 
 
Toracchio et al., 
2009  
171 archival paraffin-embedded 
lymphoma specimens 
PCR analysis and 
immunohistochemistry 
USA 
Part A=10/44 (23) 
Part B= 4/127 (3) 
 
Zekri et al., 2007 
 
Lymphoma samples and Control 
samples 
PCR Egypt 
 
83/158 (54) 
4/34 (12) Control 
 
(147). 
Different studies have provided evidence for the  detection of sequences of SV40 DNA with human 
lymphomas and other lymphoproliferative disorders (Table 1.2). However, many studies still could  
not detect SV40 sequences in their samples (148, 149). The inability of these studies to detect SV40 
NHL patients 29/68 (43) 
H L patients 3/31 (9) 
11/79 (13.9) 
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 DNA in their samples could be attributed to laboratory technical difficulties in the detection of 
SV40; and to geographic variation relating to the distribution of SV40 contaminated polio vaccines 
and/or  characteristics of a particular population along with existence of variation in the ethnic 
susceptibility to SV40.  
 
In fact, the role of some viral agent such as EBV have been strongly implicated in certain 
lymphoproliferative disorders. The main question now is: can SV40, just like in the case of 
mesothelioma where it has been identified as co-carcinogen with asbestos (130), be also identified 
as a causative agent?,  or can it have a role to play in lymphomagenesis/ NHL?.  Other questions 
raised by studies investigating the role of SV40 in lymphoproliferative disorders include: ―is the 
association of SV40 with NHL causal or incidence?; does SV40 have a hand in the proliferation of 
tumourigenic events in NHL?; do tumours offer a microenvironment that favours viral replication in 
humans with latent SV40 infection?‖ (103).  Honestly, the answer to the above questions are yet to 
be strongly established experimentally.  
 
Nonetheless, there have been previous and present studies investigating the presence of SV40 in 
human lymphoproliferative disorders though only few studies such as Dolcetti et al., and Shaikh et 
al., have focused on the SV40 interaction with human B lymphocytes (38, 118). Despite the 
limitations of  Shaikh et al in their study, they tried to detect SV40 DNA sequences using samples 
collected at only one early time point when little effects of SV40 would be expected. The results of 
the above two studies indicated the potential role of SV40 in Lymphomagenesis and call for further 
investigation to examine the relationship and effects of SV40 with human lymphocytes.  
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 2. Objective of the experimental thesis 
    imian Virus 40 (SV40), a small DNA  tumour virus of approximately 5.2 kb,  has been fully 
characterized as a transforming and tumourigenic viral agent. It transforms different types of animal 
and human cells, and when inoculated by different routes in experimental animals, it induces bone 
and brain tumours, mesothelioma and lymphoproliferative disorders. SV40 footprints in humans 
have been found to be associated at high prevalence with specific human tumours of same as are 
induced by SV40 in rodents. It has also been detected, although at lower prevalence, in blood 
samples from healthy donors. These SV40 properties are mainly related to the activities of its two 
oncoproteins, the large Tumour antigen (Tag) and the small tumour antigen (tag), which display 
multiple functions. In cell transformation and tumourigenesis, Tag target key cellular products, such 
as the tumour suppressor p53 and pRB family proteins, inactivating their functions. 
 
However, different studies have provided no evidence of detecting SV40 sequences in their 
experiments/samples and its ability to infect blood cells, probably due to laboratory technical 
difficulties in detection of SV40, geographic variation relating to the distribution of SV40 
contaminated polio vaccines and/or characteristics of a particular population along with existence of 
variation in the ethnic susceptibility to SV40. As consequence of these conflicting results, 
considerable debate has developed in science community. The problems related to SV40 infection 
in the human population and its contribution to human cancer have been summarized in an 
evaluation by the ―Immunization Safety Review Committee‖ established by the Institute of 
Medicine of the American National Academies. Detailed investigations aimed at verifying whether  
SV40 may infect human lymphocyte cells from healthy individuals are of paramount importance in 
revealing the capability of SV40 to spread in humans and in studying its contribution in the 
onset/progression of lymphomagenesis.  
 
S
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 Moreover, the relevance of viral infections to the onset/progression of human hematologic 
malignancies and other blood diseases is still a matter of active investigation.  In as much as 
contrasts of opinion on the role/association of SV40 in Lymphoproliferative disorders has continued 
for an age, indebt studies on the interaction between lymphocytes and SV40 has not yet been fully 
described. My  research aimed to analyze the effect of SV40 infection on human B and T  
lymphocytes  so as to gain insights into the pathogenesis of SV40 in human disease. The project 
was therefore designed to experimentally verify (a) SV40 DNA sequences in 60 healthy blood 
donors from Aviano Cancer Center,  (b) characterize infection of strain 776 SV40 in T and B cells 
and transfection with pSV3neo plasmid (a plasmid with early region of SV40) in B cells obtained 
from healthy blood donors so as to understand the possibility of susceptibility of B and T cells, their  
transformation/ immortalization and production of viral progeny.  
 
In my method, continuous analysis of extracted DNA samples from healthy blood donors,  SV40-
infected/transfected B and T lymphocytes then allowed: (i) examination of the effect of SV40 
infection on the cell proliferation and viability of B/T-lymphocytes using trypan blue 
analysis/Alamar blue assays on cultured cells; (ii) examination of the presence and expression of 
viral sequences with quantitative/qualitative PCR, RT-PCR and  FACs analysis; (iii) examination of 
the morphological and immunological characteristics with immunoflorescence and scanning 
electron microscope; and (iv) production of  viral progeny using cytopathic effects assay and plaque 
assay.  
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 3. Materials and methods 
 
3.1:  PBMCs and Isolation B/T cells from buffy coats 
Buffy coats were obtained from the blood bank of St. Anna’s University-Hospital of Ferrara. 
PBMCs (n=1x10
9
) were isolated by density gradient centrifugation over Ficoll-Histopaque 1077 
(Sigma-Aldrich, Milan, Italy). Then, PBMCs were cultured overnight with RPMI 1640  (Euro 
Clone, Milan, Italy) supplemented with 10% Fetal bovine Serum (Euro Cline Milan) and 2%  
Penicillin/Streptomycin (P/S) at 37°C and 5% CO2 in a humidified atmosphere. Human B and T cells 
were isolated from PBMCs by deplation method using immunomagnetic DYNAbeads (Invitrogen 
Milan, Italy) according to the instruction of the manufacturer. Human B and T cells were maintained 
in culture in RPMI 1640 medium (InVitrogen, Milan, Italy) supplemented with 10% FBS 
(Euroclone, Milan, Italy), 2 mM L-glutamine, 2% (P/S) and 2%  phytohemagglutinin (PHA) 
(Gibco, Invitrogen, Milan, Italy) at 37°C and 5% CO2 in a humidified atmosphere, in 6 well plates 
at 2 x10
6
 /ml cells. Trypan blue assay was employed to assess the proportion of viable cells by an 
optical microscope. Cell count (n= 2x10
6
/ml) was used for percentage survival calculation. 
Percentage survival= number of viable cells at test time point/number of viable cells at time zero x 
100.  
 
3.2:  Flow cytometric analysis, infection and transfection of human B and T cells  
Flow cytometer of BD FACS CALIBUR was used to analyse the expression of  human  B and T 
cells markers isolated by immunomagnetic dynabeads. B cells were investigated with the 
monoclonal antibodies, CD19, anti-CD45 and anti-CD3, then labelled fluorescein-isothiocyanate 
(FITC)-conjugated (Becton Dickinson, Milan, Italy).  
SV40 infection was carried out under Biosafety Level 2 safety precautions. Human B lymphocytes 
(n=2x10
6
/ml) were infected with the SV40 strain 776 in RPMI supplemented with 1% FBS and 1% 
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 of P/S. Viral inoculum, diluted in medium with 1% FBS was employed at m.o.i. of 0.1 p.f.u./cell. 
Incubation was carried out for 2hrs at 37°C, 5% CO2, with occasional rocking, in 6 well plates. The 
viral inoculum was then removed, and after rinsing with 1% saline, cells were maintained in culture 
in complete medium at 37°C, 5% CO2 in a humidified incubator. Different assays were carried out 
at different time post infection (p.i.) to verify the SV40 infection of B cells. The culture medium 
was changed twice a week. 
 
pSV3neo DNA (figure 3.1), 500 ng, was transfected into B cells (n=2x10
6
/ml) in six well plates 
using Lipofectamine
TM
 LXT and PLUS
TM
 Reagents (Invitrogen, Milan Italy) according to 
manufacturers instruction. Transfected B cells were maintained in culture in the same manner as 
described above for the SV40-infected cells. 
 
 
 
 
 
 
 
 
 
3.3:  Cell lines 
CV-1 (Figure 3.2A) cell line was initiated in March of 1960 by F. C Jensen and his colleagues with 
a tissue section excised from kidney of a normal adult male African green monkey (Cercopithecus 
aethiops). CV-1 cell lines exbits the morphology of fibroblast and has the capacity to grow 
adherently to glass or plastic surfaces. CV-1 cells are known to be subject to several viruses such as 
SV40, poliovirus 1, herpes simplex, california encephalitis and Estern and Western Equine 
 
Figure 3.1:  structure of the 
pSV3-neo plasmid with intact SV40 
early region. The pSV3neo plasmid is 
composed of pBR322 origin of DNA 
replication (pBR322 ori) a β-
lactamase gene (AMP
R
); a neo gene 
(1.4 kb fragment); and the SV40 
DNA sequence. The SV40 origin of 
DNA replication (SV40 ori) and SV40 
early promoter are present on a small 
fragment immediately 5’ to the neo 
segment (150). 
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 encephalitis. Being permissive to SV40 infection, were used as positive controls to verify the C.P.E. 
CV-1 cells, were grown in Dulbecco’s modified Eagle’s medium–F12 (DMEM) (Euroclone, 
Celbio, Milan, Italy), supplemented with 10% FBS and 2% P/S. 
WI38- VA13 (Figure 3.2B) is an SV40 transformed cell line derived from embryonic lung human 
strain WI-38 subline 2RA fibroblast cells (151, 152). WI-38 VA13 is used as a Tag positive control 
and were maintained in culture with Minimum Essential Medium (EMEM) (Euroclone, Celbio, 
Milano Italy) supplemented with 10% FBS and 2% P/S. 
 
 
 
 
 
 
 
 
 
 
3.4:  Alamar Blue assay for cell viability and proliferation 
Normal, SV40-infected and pSV3neo transfected B-cells were collected from culture flasks, 
counted with  Hemacytometer,  brought first to a concentration of 2x 10
6
 cells/ml and subsequently 
seeded in duplicate wells of a 24-well plates with 1 ml of  RPMI medium containing 1% FBS and 
5% Alamar blue (AB), plates were maintained at standard culture conditions of 5% C02 in air at 
37°C. Optical density of 100 μl of the medium in 96 well plates was measured at 570 nm and 620 
nm with a standard spectrophotometer at 5 hours in different days of p.i. As a negative control, AB 
was added to medium without cells (153, 154) . The percentage reduction of Alamar blue was 
 
 
 
Figure 3.2: positive control Cell lines. (A), Normal African Green 
Monkey kidney Fibroblast cells (CV-1), (B) Embryonic lung Human Strain 
WI-38 Subline 2RA Fibroblast cells (WI38-VA13). 
(A) (B) 
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 calculated using the formula:  = [ ALW - (AHW x R0) ] x 100,   Where: ALW = absorbance at 
lower wavelength minus the media blank, AHW = absorbance at higher wavelength minus the 
media blank and R0 = Correction factor [Absorbance of AB in media – Absorbance of media only 
at lower wavelength/Absorbance of AB in media – Absorbance of media only at higher wavelength] 
(155). 
 
 
 3.5: Population doubling time (PDT)  
 To determine the population doubling time (PDT) of transformed cells, B transfected and infected 
cell numbers from 80-d.p.i. were determined in triplicate using haemocytometer. PDT was 
calculated at 48 and 72 hours intervals using the formular: PDT= t log 2/ log Nt- log No, where t is 
time period, Nt is number of cells at time t and No is initial number of cells (156, 157). 
    
3.6.1:   DNA Purification (FOR EXPERIMENT I) 
The subjects under investigation were 60 healthy blood donors. All the  60 subjects were from the 
same area with residual environmental asbestos pollution (Aviano). The persistent environmental 
pollution of asbestos is being suspected as the cause of a higher mortality from MM among the 
inhabitants of the area regardless of occupational history. Blood from 60 subjects were collected 
and stored at –80°c  till  the time of use for laboratory analysis. 500µl of the blood was digested 
with 1% SDS and 500µg/ml protinase K (Sigma, Milano Italy). The DNA was purified using a 
mixture of phenol-chloroform-Isoamyl alcohol in the ratio of 25:24:1 and dialyzed overnight with 
TEN buffer (10mM Tris, pH7.5, 1mM EDTA, 1M Nacl). It was further purified overnight with TE 
buffer in the absence of  Nacl  
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 3.6.2:  DNA and RNA extraction (FOR  EXPERIMENT II and III) 
 DNA was extracted using a commercial kit (Qiagen kit, Invitrogen, Milano Italy) as directed by the 
supplier, using 1x10
6/
ml cells density of lymphocyte cells. DNA was also extracted from cell 
sample pellets (B and T infected and normal lymphocyte cells, WI-38 VA13 cultured cells and 
pSV3neo transfected B cells). Pellet was digested with protein kinase buffer, RNase (10μg/ul) and 
SDS of 10%, DNA was  purified using a mixture of phenol-chloroform-isoamyl alcohol in the ratio 
of 25:24:1 and dialyzed overnight with TEN buffer (10mM Tris, pH7.5, 1mM EDTA, 1M Nacl). It 
was further purified overnight with TE buffer in the absence of NaCl (40a).   
 
Total RNA was extracted from 5x10
6
 WI38-VA13 cells, infected, transfected and normal samples 
of B cells, using TRIzol reagent (Gibco/BRL, Milan, Italy) according to the manufacturer’s 
instructions.   
 
 
 
3.7.1:  Polymerase Chain Reaction [PCR] (FOR  EXPERIMENT I)  
 
SV40 DNA from 776 strain was used as the positive  control in PCR amplification.500ng DNA 
samples from 60 healthy blood donor were initially verified for PCR analysis using a control 
reaction designed to amplify β-globin gene sequences to check for PCR Compatibility. The 
parameter cycle for β -globin gene amplification were 5 min at 94°C., 30 s at 56°C., 30 s at 72°C. 
for 35 cycles (40a). All samples were further investigated for amplification of SV40 sequences. To 
avoid PCR contaminations, all reagents for both DNA extraction and PCR analysis were 
exclusively used for the experiments of this study. All samples were analyzed for SV40 Tag 
sequences of SVINTfor-SVINTrev and SV.for2-SV.rev specific for SV40 early region sequ and 
later sets of primers served for nested PCR (nPCR). The SV.for2-SV.rev  has the  cycle parameter 
of 5mins at 94°c, 1min at 94°c, 1min at 55°c, 1min at 72°c for 45cycles and SVINTfor-SVINTrev 
with cycle parameter of 15mins at 94°c, 1min at 94°c, 45s at94°c, 45s at 60°c, 1min at 72°c for 
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 40cycles.   Ten micro liters of each PCR reaction were loaded on 2% agarose gel and eletrophoresed 
in 0.5x TAE buffer [40 mM Tris- acetate EDTA (pH 8)], stained with ethidium bromide, and 
photographed. The molecular weight marker was the gene ruler 100bp. DNA from samples that 
were positive for SV40 by PCR were analyzed and  sequenced three times in both directions using 
the primers according to the manufacturer’s protocol.  
 
 
3.7.2:  PCR techniques (FOR EXPERIMENT II and III)  
 
For PCR analysis, 200ng of DNA extracted from WI-38 VA13, infected, transfected and normal B 
cells. DNA extracted from both WI38- VA13 cells and whole SV40 DNA wild-type strain 776 were 
used as positive controls while normal B cells were used as negative control (40a). PCR 
amplification of the DNA samples was determined using SV.for2-SV.rev (single step PCR) and 
Sv.for1/Sv.rev1(nested PCR). Polymerase chain reaction products (10 ul sample) were migrated in 
a 1% electrophoresis agarose gels in the presence of ethidium bromide, using a TAE 0.5X buffer 
containing 40 mM Tris-acetate, 1mM EDTA, pH 8 and visualized under U.V. light using the Gel 
Doc 2000 System (Bio-Rad, Milano, Italy). Molecular weight markers were the Gene ruler 100 bp 
(Fermentas, Milan, Italy). 
 
 
 3.8:  RT-PCR analysis  
For reverse transcriptase (RT), 0.3µg of total RNA of the samples were respectively resuspended in 
10 l of a reaction mixture made from 10x reaction buffer with MgCl2, 1 U DNase I-RNase-free 
(Fermentas, Milan, Italy) in water diethylpyrocarbonate (DEPC) and incubated at room temperature 
(RT) for 15 min. Dnase I was inactivated by adding 1 µl of 25 mM EDTA and incubating at 65°C. 
for 10 min. DNA-free total RNA was transcribed. cDNA was obtained using SuperScript II 
(Invitrogen, Milano, Italy) following the manufacturer’s instructions. cDNA was then amplified by 
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 single PCR with primers SV.for2-SV.rev and analyzed by gel electrophoresis. A house keeping 
gene, NAPDH (159) was also used to control the efficiency and reliability of the cDNA samples. 
 
3.9:  Ultrastructural studies (Experiment II-III) 
For  ultrastructural studies, Cultured infected, transfected, and normal B cells were fixed overnight 
at 4°C in 2·5% gluteraldehyde and post fixed for 2 hrs at room temperature in 1% osmium tetroxide 
and dehydrated with increasing concentration of ethanol before embedding in Araldite II resin. 
Transversally cut sections were then analyzed using transmission and scanning electron microscopy 
(TEM and SEM, Cambridge UK, model Stereoscan S-360) as described before (158, 160, 161, 
162).  
 
 
3.10:  Indirect immunofluorescence  
WI-38 VA13 expressing SV40 Tag was used as positive control in this experiment (163). WI38 -
VA13 cells were grown in 12 mm coverslip glass. T and B cells were infected or transfected as 
described above, then stained for immunofluorescence at different times p.i. Samples were 
sedimented by cytospin and analyzed by indirect immunofluorescence. Briefly, cells were fixed in 
methanol acetone (1:1) for 10 min at RT, washed in PBS, and reacted with the mouse monoclonal 
antibody against Tag, C-terminus epitopes, with Pab101 (Santa Cruz Biotecnology, Santa Cruz, 
CA, USA) (epitope between residues 512 and 708) for 1h at Room Temperature (RT) and then with 
anti-mouse IgG-FITC-conjugated (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1h at 
Room Temperature. To verify the presence of SV40 capsid proteins (VPs),  cells were reacted with 
goat anti-SV40 antiserum  (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1h at RT, and 
then with secondary antibodies of donkey anti-goat IgG-FITC-conjugated (Santa Cruz 
Biotecnology, Santa Cruz, CA, USA) for 1h at RT (B. Burmeiser et al., 2004). Cells were counter-
stained with 0.5 µg/ml of 4’,6-diamino-2-phenylindole (DAPI) (Sigma, Milano, Italy) and observed 
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 with a Nikon TE2000E microscope (Nikon S.p.A., Florence, Italy), while digital images were 
captured using the ACT-1 and ACT-2 software for the DXM1200F digital camera (Nikon S.p.A., 
Florence, Italy).   
 
 
3.11:  Cytopathic effect of infected T cells, B transfected and infected with titer 
determination 
 
Permissive CV-1 cells were used to verify the presence of SV40 virions at day 10, 40 in T cells and 
10, 40 and 60 days p. i. in infected B cells. Sonicated pellet and  medium of SV40-infected T, B 
cells were employed as inoculums in CV-1 to investigate the typical SV40 cytopathic effects 
(C.P.E.). SV40 infected T,  B-cells and medium were subjected to three cycles of freezing and 
thawing and then sonicated. Subsequently, lysated and medium were inoculated into monolayers of  
CV-1 cells (60-70% confluent) (138) and incubated for 2 hrs at 37°C, 5% CO2 with occasional 
rocking in DMEM supplemented with 1% FBS and antibiotics. After incubation, CV-1 cells were 
cultured in 24 well plates in DMEM supplemented with 1% FBS for 15 days for observation of 
C.P.E appearance. CV-1 cells infected with 10
 
to 10
6 
pfu/ml and uninfected CV-1 represented the 
positive and negative control respectively.  SV40 776 strain was used as the viral working stock as 
described previously (158). 
 
3.12:  Plaque assay 
Virus plaque assay was carried out as previously done in (164, 165, 166). Briefly,  SV40 776 strain 
virus stock solution (10
7
) was used to infect 2x10
6
/ml purified B and T lymphocytes at 0.1 pfu/cell. 
Absorption was carried out for 2hrs at 37°C, 5% CO2 in a humidified incubator in 2 ml DMEM 
medium supplemented with 1% FBS. Cells were washed with 1% PBS. 200ul dilution of 10
6 
of 
infected cells in DMEM medium supplemented with 1% FBS were inoculated into monolayer CV-1 
cells in a 6 well plates and incubated for 6hrs at 37°C. Subsequently, cell medium was aspirated 
from the plates and plated with DMEM medium solution supplemented with 1% FBS and 1.0 % 
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 agarose gel (Sigma, Milan, Italy) prepared by autoclaving at 121°C. for 20 minutes. After 
incubation for 9 days at 37°C with addition of 500ul medium every 3 days, the agarose layer was 
stained with 0.1% crystal violet. Plaques were counted and expressed as number of PFU/10
6
 cells. 
SV40 infected CV-1 at 10
1 
to 10
6 
viral titre and uninfected CV-1 represented positive and negative 
controls, respectively  (164, 165, 166). 
 
 
3.13:  Statistical Significance 
The results of Trypan blue and percentage expression of B cells from different donors were tested 
for significance using the student’s t-test (two-tailed). Differences were considered significant at p 
< 0.05 percentage and the values of the parameters analyzed are expressed as mean ± standard 
deviation (SD). The 95% confidence intervals of samples (C.I) was also reported. 
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4. Results 
Experiment I 
 Simian Virus 40(SV40) Sequences in Blood Specimens Of Healthy Individuals 
From Aviano. 
 
SV40 is a DNA virus found to be cocarcinogenic to asbestos in the pathogenesis of Mesothelioma. 
Human infected mesotheliomal cells are also found to be susceptible to SV40 with 100% of the 
infected cells expressing the SV40 T antigen (Tag). This Study investigated the presence of SV40 
sequences in 60 healthy Subjects from Aviano, an Italian town  with asbestos pollution history and 
high prevalence of mesothelioma. PCR result on the purified DNA samples from the subjects using 
SV40 as the positive control  showed that 17% (7.4–27CI) were SV40 positive. It showed that 17% 
of 60 subjects can be distinguished as possible potentially asbestos infected individuals and that 
SV40 with asbestos are really cofactors in the pathogenesis of mesothelioma. It also indicated that 
SV40 virus is being circulated in the human population. This study could serve as an 
epidemiological study that can bring SV40 virus closer to clinical practice. 
 
 
4.1:   SV40 DNA sequences in 60 Subjects of Aviano 
DNA from blood sample of 60 subjects suitable for PCR analysis were analyzed by  single PCR to 
determine the presence of SV40 sequences. SV40 Tag NH2-terminal coding sequences were 
investigated with primer sets Sv.for2-Sv.rev with 575bp.  The single PCR analyses indicated that 
SV40 Tag sequences were not present in any of the 60 DNA samples. Further analysis of the  DNA 
samples with primers set SVINTfor-SVINTrev and SV.for-SV.rev by nPCR for SV40 Tag intron 
sequences (Table 4. 2). The result showed that 10 (17%) out of 60 samples  were positive for SV40 
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 intron sequences.  A control using 15 samples negative for SV40 DNA samples analysed for nPCR 
with SV.for-SV.rev and SVINTfor-SVINTrev were also found negative. A subject is considered to 
be positive if it was detected two or more times in the nPCR with  SVINTfor-SVINTrev set of 
primers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1:subject numbers detected SV40 DNA sequences from the 60 
examined subjects. The experiment was carried out trice in each set of primers 
and a subject was considered to be  positive using the second amplification 
(SVINTfor-SVINTrev) with occurrence of at least two times. BB2-BB3 
(SV.for1-SV.rev 1, N° PCR (number of PCR). 
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 Experiment II 
Simian virus 40  Infection of Human  T Lymphocytes. 
Transfection with SV40 Tag may be a valuable method for obtaing long term human T cell lines for 
studies of both aging and immunology though it does not fully reveal the ability of SV40 virions to 
be able to infect T lymphocytes. The present study investigated human T lymphocytes isolated by 
immunomagnetic separation from peripheral blood mononuclear cells (PBMCs) of healthy blood 
donors, infected with simian virus 40 (SV40) and then monitored for evidence of a productive 
infection. Trypan blue analysis up to 80 days post infection revealed viability and plorification 
capacity of the infected cells. SV40 sequences were detected in T infected cells up to 80 days post 
infection (p.i.) with PCR tecnique. Immunofluorescence images showed the presence of SV40 Tag 
and Viral proteins in T lymphocytes from 3 days p.i to 40 days p.i. Hence, our data indicated that 
human T lymphocytes can be infected by this small DNA tumor virus.  
 
Human T cells purified by immunomagnetic separation from the PBMCs of blood donors had a 
population purity of > 98%, as determined by flow cytometry using CD3 and CD45 mAb, as 
membrane markers. This  remarkably showed that, the used T cells were normal human T cells of  
healthy  donors.  Then, the T lymphocytes were infected by SV40 and monitored in culture for 80 
days post infection.  
 
4.2: To investigate the Viability of the SV40 Infected T lymphocyte cells 
 
The viability and proliferation rate between the normal  and infected T cells was quite 
distinguishable.   The trypan blue exclusion analysis employed showed increase in the number of T 
SV40 infected cells from the initial starting number of 80x10
6  
total of every infected cells (Figure 
52 
 4.1). In the normal cells, drastic cell death was observed and the cells lasted for about 5 days in 
culture (Figure 4.1), and the T infected cells continued to be viable in culture but exhibiting slow 
decrease in number of  SV40 viral cells  as observed in (118). 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3:  SV40 sequence analysis in infected  T cells by single and nested PCR 
 
In further assess of the SV40 specificity, the highly conserved SV40 Tag domains in PCR analysis 
is similar to the SV40-776 wild type repeatedly detected in human tumors and healthy human 
tissues by many investigators. The PCR analysis of the SV40 DNA from infected cells using B-
globing control gene primers indicated that DNA of the infected cells were of SV40 776 viral 
 
Figure 4.1. Figure 1. Normal (■) and SV40-infected (▲) T lymphocytes. In our 
culture conditions, the majority of normal T cells (with PHA ●, or without PHA ■) 
remained viable for up to 5 and 3days, respectively, while SV40-infected T 
lymphocytes were viable for up to 80 p.i. The error bars represent averages of results 
of T cell cultures obtained from 6 donors. 
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 particle, (Figure not shown). This indicated that no deletions or rearrangements occurred during the 
long-term cultures (40, 64). 
 DNA sequences was present in T cells culture infected by SV40 (Figure 4.2). SV40 Tag sequences 
is found with single PCR using SV.for2-SV.rev set of primers (Pancaldi et al., 2009) up to 30 p.i 
both in supernatant and pellet (Figure 4. 2a). Then, in further analysis up to 80 days post infection 
(p.i.) in pellet with nested PCR (Figure 4.2b) using set of primers specific for SV40 early region 
sequences (Table 4.2), SV40 DNA sequences was detected.  Tag was also detected by RT-PCR 
using  primers specific for SV40 early regions. The WI38-VA13 used as positive control with SV40 
776 also tested positive while T normal cells used as negative control was negative as expected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Single and Nested PCR Analysis of SV40 DNA Sequences up to 
80 days Post Infection using set of Primers  SV.for2-SV.rev (A) and SV.for1-
SV.rev1(B), (C) RT-PCR of infected T cells up to 40d.p.i. DNA and cDNA 
(WI38-VA13 used as positive control), M(molecular weight maker-100bp), 
C(Normal T cells), R(PCR Control).   
B 
A 
 
575bp 
172bp 
C 
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 4.4:  SV40 Tag oncoprotein and capsid VPs expression in T lymphocytes 
For the presence of SV40 Tag and VPs expression the indirect immunoflourescence was employed 
(Figure 4.3). SV40 Tag and VPs was observed in T SV40 infected cells up to 50-d.p.i.   
Immunofluorescence images revealed Tag protein in human T cell infected by SV40 virions up to 
50-d.p.i. (Figure 4.3a). In human T cell SV40-infected, VP1 were detected by immunofluorescence, 
up to 50 days (Figure 4.3b). T infected cells showed vacuole cytoplasmic expression in both Tag 
and VPs. This showed that early and late viral genes were expressed in T SV40 infected cells. After 
30-50 days infection with SV40, T cells decreased in number dramatically. After this period, the 
viral proteins were not checked again using immunoflourescence staining. 
 
  
 
 
 
 
 
4.5:  SV40 Effective Production Of Progeny by infected T cells 
Cytopathic effect was employed to observe the rate of multiplicity and progeny release in T SV40 infected 
cells of 10 and 40 d.p.i with CV-1 monolayer cells. Aliquots of  infected cells (10
5
) and its medium (5ml), 
sonicated  and not sonicated, were used as inoculums to CV-1 permissive cells. Indeed the SV40 infected T 
cells showed cytopathic effect with CV-1 at different viral titers (Table 4.3). The cytopathic effect was 
characterized with cytoplasmic vacuoles surrounding the nuclear membrane which is a typical SV40 
cytopathic effect. 
      
Figure 4.3: 
 Immunoflourescence 
staining of T cell (a) Tag, 
A,C,D, (T cell infected with 
SV40), B,D,F, (WI38-VA13 
used as positive control). C,D 
(4’, 6-diamino-2-phenylindole 
(0.5 mg/ml)[DAPI] used to 
visualize the nucleus), 
E,F(Merged Image). (b) 
VP1, A,C,E(T cell infected 
with SV40) D,E,F (WI38-
VA13),C,D (DAPI), E,F 
(Merged). 
(b) 
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4.6: Structure distortion in SV40 infected T cells 
 
To observe ulteration in the structure of the T infected cells, a transverse electron microscope 
(TEM) was employed and the images were noted as mentioned in materials and method. Indeed, 
visible changes in transverse structure was detected in transfected and infected cells (Figure 4.4). 
Changes was observed from 10d.p.i.  Different changes were observed in the nucleus and cytoplasm 
which were very similar to that of SV40 infected cells (Figure 4.4B). Characteristics observed was 
also related to that seen in Leukemia cells (Figure 4.4B-E).  
 
 
 
 
 
Type of cell cultures Post 
infection 
day 
Type of 
sample 
Titer 
Human T Lymphocyte 
SV40 infected  
10  cells 10
3
 
pfu/ml 
Human T Lymphocyte 
SV40 infected 
40 cells  10
3
 
pfu/ml 
Human T Lymphocyte 
SV40 infected 
10 medium 10
2
 
pfu/ml 
Human T Lymphocyte 
SV40 infected 
40 medium 10
2
 
pfu/ml 
Table 4.3: Viral titers showed by SV40 776 strain released by 
infected T human lymphocytes and CV-1 cells (45-54-2CV-1). 
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Evidently, after an initial phase of the semi-permissive T cells, as evidenced by Tag, Vps 
expression, and production of virions, there followed a second phase of T cells fully permissive to 
the virus. After 50- d.p.i, in fact, there seems to appear a distinct phase of permissive cells to the 
virus, the lytic cycle and cell death. The PHA stimulated T cell replication and the establishment of 
a semi-permissive stage for the development of cell culture propagation for T cell. The study also 
indicated that SV40 can establish a persistent infection in human T cells lasting after the ―crisis‖ 
stage. 
 
 
 
Figure 4.4: TEM  results of T  cells (A) Normal human T cell x6,300, (B) typical T  cell 
SV40 infected after 10p.d.i, Cell with hairy projection  similar to hairy cells of Leukemia, 
x13.000 (C) T cell of 10d.p.i with large  size, voluminous indented nucleus and clear cytoplasm, 
x5.000.(D)Filamentous projection of the cytoplasm. typical structures found in hairy cells, 
x40,000. (E) Cytoplasm with many organelles, multivasicular bodies and ribosomal- lamella, 
x80,000 
 
 
 
57 
 Experiment III 
Transformation of human B cells by SV40, a small DNA tumor virus  
 Simian virus 40 (SV40) is a small DNA virus linked with specific human cancers such as 
malignant pleural mesothelioma, brain and bone tumors, leukemia, lymphoma diseases. It could 
also be detected in healthy blood donors. While debate and rate of prevalence/detection of DNA 
sequences in human cancers and non-Hodgkin lymphomas (NHL) is at increase, indebt studies on 
the interaction between lymphocytes and SV40 has not yet been fully described.  Hence, our effort 
to bring forward this study with purified human B lymphocytes isolated from the peripheral blood 
mononuclear cells of healthy blood donors, experimentally infected and transfected, monitored for 
evidence of infection, transformation/immortalization and release of progeny using continuous 
analysis with different parameters. 
 
 SV40-positive B lymphocytes extended their lifespan up to 100-d.p.i. Expression of SV40 Tag was 
detected in infected and transfected B cells up to 90-d.p.i with immunoflourescence while the viral 
capsid protein VP1 was detected up to 50-d.p.i. in infected cells. SV40 viral progeny was 
continuously produced from day 10 to 60 d.p.i in wild SV40 strain infected cells. SV40 DNA 
sequences were detected in both infected and transfected cells up to 100-d.p.i. These data indicate 
that human B lymphocytes can be efficiently infected with SV40. Ultra structural morphology were 
detected in both infected and transfected cells. Normal B human cells lasted about 6 days in culture. 
More than 50% of these B lymphocytes were transformed using the B cell ultra-structural analysis 
and characteristics of the cells in culture. 
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 This study detailed the SV40 infected and pSv3neo transfected B lymphocyte realized from 
Peripheral blood mononuclear cells (PBMCs) of healthy blood donors and observed in culture for 
three months . The cells observation commenced from 3 days of post infection to 100 days. 
 
4.7:  FACs analysis, infection and  transfection  
To determine the population number of purified human B lymphocytes, isolated from PBMCs of 
blood donors using immunomagnetic dynabeads, a FACs analysis was employed. B cells showed 
different expression percentage with maximum population of 95.1% purity from the 6 different 
donors  (Figure 4.4), as determined by flow cytometry using the monoclonal antibodies, CD19 with 
anti-CD45 and anti-CD3 (Table 4.4). 
 
Subsequently, the purified normal B lymphocytes were infected with SV40 or transfected with  
pSV3neo as described in materials and methods, then observed in culture for 100-d.p.i.  
 
 
 
 
 
 
 
 
 
 Figure 4.5: FACs results of % population of normal B cells isolated from 
PBMCs of 6 Healthy blood donors buffy coat. Depicted also is little % population of  
T cells (red). Differences in the % of B cell expression of the different donors was not 
statistically significant. P < 0.05 .   
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 Antibody Type Protein/ Cell Target Manufacturer 
CD19 Monoclonal marker B normal Cells Sigma (Milano, 
Italy) 
CD3 Anti-membrane 
marker 
T normal Cells ” 
CD45 ” Hematopoetic cells ” 
PAB101 Mouse monoclonal, 
primary 
Tag (B transfected and 
infected cells) 
Santa Cruz 
Biotechnology, CA, 
USA. 
Goat SV40 
anti-serum 
 
” 
VP1 (B transfected and 
infected cells) 
 
” 
 
IgG-FITC 
 
Anti-mouse, 
secondary 
 
Tag (” ) 
 
” 
 
Donkey 
anti-goat 
IgG-FITC 
 
Anti-goat, 
secondary 
 
VP1 (”) 
 
” 
                 Table 4.4: list of antibodies used in FACs and Immunoflourescence Analysis 
 
 
4.8:   Cell viability and proliferation capacity 
To monitor the viability and proliferation capacity of infected and transfected B cells, trypan blue 
and Alamar blue assays were carried out, respectively. Cells were followed in culture at different 
d.p.i. with trypan blue. Indeed, SV40-infected B cells and pSV3neo transfected cells  showed 
increase in number at day 5 of p.i. from the initial number of cells; after this period, there was 
gradual decrease and death of cells until 80-d.p.i (Figure 4.5), with pSV3neo transfected cells 
retaining more cells at 80-d.p.i in culture than B cells infected with SV40.  Suprisely,  continous 
culturing of the cells gave rise to cell increse between 80 – 90 d.p.i. with drastic but constant 
decline between 95- 100-d.p.i. In all, there was no statistical significance in viability of B cells 
infected and transfected,  while the infected and transfected cells showed prounounced statistical  
 
60 
 significance with p= 0.02 and 95% confidence interval of – 71.94-173.4 over normal B cells. The 
normal B cells lasted between 1 to 6 days in culture (Fig.4.5).  
 
Similarly,  Alamar blue assay was also performed at 3 and 30-d.p.i for the cells in culture so as to 
monitor the proliferation and viability as well. Alamar blue asssay showed the percentage of 
reduction in cell samples to be the same with trypan blue analysis (Figure 4.6), with reduction in the 
ability of the cells to reduce alamar blue at advanced stage of post infection in culture. The graph 
linear of the cells depicted a rise at 3-d.p.i. in the transfected and infected cells but down stream 
arrow  linear at 30-d.p.i. in culture (Figure 4.6AB, CD).  In B normal cells, a fall in the linear lines 
was observed at 3-d.p.i. and were totally off in culture as at 30-d.p.i. (Figure 4.6E).  
 
 
 
 
Figure 4.6:Trypan blue analysis depicting % survival of  normal, transfected  and 
infected B cells in culture from 5-100 p.i. Normal B cell (triangular line) lasted between 1-
6 days in culture. B+ SV40 (B SV40 infected cells), B+ pSV3neo (B pSV3neo transfected 
cells).   
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Figure 4.7: graphs showing percentage of alamar blue reduction of B cells with 
different incubation periods and at different initial cell densities (A), B cell SV40 
infected 5 p.i, (B), B cell  pSV3neo transfected 5 p.i, (C), B cell SV40 infected 30 p.i, 
(D), B cell pSV3neo transfected 30 p.i, (E), B normal cells 3 days in culture. 
 
 
E 
 
 
 
 
 
E 
A B 
D C 
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 4.9: Growth Behaviour of Infected and Transfected Cells 
To have more insight on the proliferation and viability of the infected and transfected cells, the 
growth behavior investigation was carried out by finding the population doubling time as described 
in materials and methods. Subsequently, infected and transfected cells from 80-d.p.i. doubling time 
was calculated at 48 and 72 hours intervals. Figure 4.4 represents the linear of the mean results from 
the two interval  times experiment. The B cell SV40 infected cells (Figure 4.7A) showed a slight 
difference in both doubling time and growth capacity from B cell pSV3neo transfected cells (Figure 
4.7B). 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
Figure 4.8: population doubling time of  cells. (A), B cells SV40 infected  (B+ SV40),  (B), B 
cells pSV3neo  transfected (B+pSV3neo).   
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 4.10: Detection of SV40 DNA sequences in infected and transfected B  
      cells  
 
SV40-infected and pSV3neo transfected B-cells were investigated for SV40 DNA sequences by 
single PCR using primers specific for SV40 sequences (Table 4.2) for the period of 3-100-d.p.i. 
PCR detected Tag NH2-terminal coding sequences with product size of 575 base pair (bp) in both 
SV40 infected and pSV3neo transfected B-cells up to 100-d.p.i. (Figure 4.8 A,B). The result 
generally showed that SV40 sequences were detected in infected and transfected B-cells at every 
inspected time, and consistent during cell culture even when cells entered into crisis (Figure 4.8C). 
This indicated stable integration of SV40 Tag into B cells.  As anticipated, DNA samples from 
normal human B cells were SV40-negative. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: PCR and RT-PCR analysis for the infected and 
transfected B cells  (A), PCR of B cells SV40 infected of 3-100 p.i, (B),  PCR 
ofB cells pSV3neo transfected of 3-100 p.i, (C), RT-PCR of B cell SV40 
infected, (D), B cell pSV3neo transfected, B+ pSV3neo (tranfected b cells), 
B+SV40(infected B cells), C+ (SV40 776- positive control), DNA (WI38-
VA13), cDNA(WI38-VA13 cDNA), C- (B cells untransfected- negative 
control,  R (PCR control), bp (base pair), MW (Molecular weight marker-
100bp). 
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 4.11: Expression of SV40 Tag and VP1 in Human transfected and 
infected B cells 
 
Having verified the SV40 sequences with PCR in the transfected and infected B cells, expression of 
SV40 Tag and VP1 was assessed in the cells using RT-PCR and immunoflourescence parameters 
respectively.  A single RT-PCR was performed on total cytoplasmic RNA from SV40 infected and 
pSV3neo transfected B cell samples using a  primers specific for the Tag sequences SV.for2-SV.rev 
located upstream and downstream of the Tag intron. The cDNA samples for B cell infected with 
SV40 produced a fragment of 229bp and the viral DNA of 575 as well (Figure 4.8C). The pSV3neo 
transfected  B cell was absent (Figure 4.8D) probably due to small concentration of cDNA. Only the 
DNA fragment was detected with nested PCR amplification reaction with primers Sv.for1/Sv.rev1 
yielding an amplification of 172bp (Figure not shown). Tag mRNA was detected up to 20-d.p.i. in 
infected cells.   
 
Immunoflourescence experiments established the presence of SV40 Tag proteins in both SV40 
infected and pSV3neo transfected B cells and in SV40 transformed cells of WI38-VA13 human 
fibroblast (Figure 4.9). The Tag was detected in both the infected and transfected cells from 8 to 90-
d.p.i. (Figure 4.9 a-o). This indicated stable integration of SV40 Tag into B cells. As anticipated, 
Tag was also detected in WI38-VA13 used as the positive control (Figure 4.9,g ,h, i.).  
  
Correspondingly, VP1 protein was also expressed in SV40 infected B cells but absent in pSV3neo 
transfected cells (Figure 4.10).  The VP1 expression was detected up to 30-d.p.i. in the infected 
cells and exhibited mainly dense VP1 staining at the cytosol (4.10,a,d,g), which is very common 
with SV40 infected cells. The B cells showed large B cell morphology with diffuse cytoplasmic 
staining. 
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Figure 4.10:.  Immunofluorescence detection of SV40 Tag in infected, transfected B cells 
and WI38-VA13. Fixed cells were incubated with PAB101 to localize the Tag, an adequate secondary 
antibody conjugated with FITC was used to reveal the signals (a,d,g,j,m). Nuclei were visualized with 4’, 
6-diamino-2-phenylindole (0.5 mg/ml) DAPI (b,e,h,k,n). Depicted also is merge Images of Tag proteins 
in B+SV40, B+PSV3neo and WI38-VA13 cell lines (c,f,i,l,o). B+ SV40 (B cell SV40 infected of 
8p.i(a,b,c) and 90p.i ( j,k,l). B+pSV3neo (B cell pSV3neo transfected cells of 8p.i (d,e,f) and 90p.i  
 MAGNIFICATION 20x 
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4.12:  Structure distortion in transfected and infected B cells 
 
To observe the possibility of a change in the structure of the B cells infected and transfected, a 
transverse electron microscope (TEM) was employed and the images were noted as mentioned in 
materials and method. Indeed, visible changes in transverse structure was detected in transfected 
and infected cells (Figure 4.11). The pSV3neo transfected B cells of 50-d.p.i. showed large but  
 
Figure 4.11:  Detection of VP1 in infected and transfected human B cells (m,n,o). WI38-
VA13 (positive control- g, h,i,). B, Cellular localization of VP1 proteins I of  B+SV40, 
B+PSV3neo and SV40-immortalized fibroblasts WI38-VA13(Control). Fixed cells were 
incubated with goat anti-SV40 serum  to localize the VP1 with adequate secondary antibody 
conjugated with FITC to reveal signals. FITC (a,b,c). DAPI (d,e,f) Merge (g,h,i). 
                                                                                    MAGNIFICATION 40x 
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 many vacuole with some particles, indent condensed and clear nuclei. The electron dense reaction 
product is seen to be confined to chromatin portion of the nucleus which is often in striking contrast 
to the B normal cells (Figure 4.11A). In B cells infected with wild 776 SV40 strain of 3 and 6-d.p.i. 
showed more larger vacuoles with indented and empty or clear  nucleoli as observed in plasmid 
tranfected cells (Figure 4.11 B,D). Visible also, is hair projection of the cytoplasm  (D). The hairy 
projection feature is more pronounced in the pSV3neo transfected B cells of 10-d.p.i. (4.11,C). 
Some B transfected and infected cells of 50-d.p.i. depicted clear cytoplasm with indented and 
perforated nucleoli respectively (Figure 4.11, E, F).  Ruptured cell wall with more lax chromatin,  
no cytoplasm and reduced indented nucleoli was also observed. The advanced stage of nuclear 
membrane restitution without any evidence of cytoplasmic division suggests the formation of a 
binucleated cells (F, x 10,00). Figure 4.11G, shows normal B cells or uninfected, untransfected cells 
(x 10,00).  
 
Generally, B cells transfected and infected depicted features similar in other SV40 infected 
lymphocytes and in lyphomagenesis disorders such as Leukemia, Hodgkin deseases, and HTLV-1 
infected cells (167, 168).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12:  transmission 
electron microscope for ultrastructural 
observation  in B infected and transfected 
cells. A, C, E, B are pSV3neo transfected 
cells (X 15.0, 9.00, and 15.0 respectively), 
B, D, F, B are cells infected with wild 
SV40 776 (X 5.00,8.00 and 10.0), G, B 
normal cells (X 7.00).   
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 4.13:  Effective production of progeny in infected and transfected B cells 
with CV-1 permissive monolayer cells 
 
Cytopathic effects (C.P.E.) assay was employed to observe the rate of multiplicity of  B infected 
and transfected human cells. Based on this, aliquots of the cells (10
5
) and their medium of 10, 40 
and 60 d.p.i. were inoculated to CV-1 monolayer cells and monitored for 15 days. In this 
experiment, the C.P.E. observed in CV-1 cells infected at different multiplicity of infection (MOI) 
from 10
1
-10
6
 served as positive control (Figure 4.12 A [10
6
], B[10
1
]). As anticipated, the SV40 
infected B cells showed C.P.E. with CV-1 which can be differentiated with cytoplasmic vacuoles 
surrounding the nuclear membrane, which is the main characteristics of  SV40 infected monolayer 
cells (4.12,G-L).  C.P.E. appeared as plaques on the 10
th
 day in plates of 10-d.p.i. in B cell SV40 
infected cells (4.12,G, J) and later spread across the cell monolayer over longer periods in culture. 
Apparently,  C.P.E. was observed in pSV3neo transfected B cells at 10-d.p.i. but no C.P.E. in both 
cell and medium of 40-d.p.i. (Figure 4.12 C, E, F). The C.P.E. was also visible in infected cells of 
40 and 60-d.p.i. cell and medium (H, I, K, L). No C.P.E. was observed in CV-1 uninfected cells 
used as negative control (D).  Additionally, different titers were observed in the cells that showed 
C.P.E. with CV-1 using end-point dilution method (Table 4.5). 
 
 
4.14:  Plaque assay viral titer 
 
Additionally, the study tried to observe viral titer using plaque assay as did in cytopathic effect 
analysis. For this purpose, infected and transfected B cells were treated as mentioned in materials 
and methods section and incubated with DMEM medium containing 1.0% of agarose gel for 6 days. 
Plaque assay was visualized with 0.1% crystal violet (Figure 4.13). Indeed plaque was observed in 
B cell SV40 infected of 10-d.p.i. with titer of 4x10
4 
in cell and 1x10
3
 in medium (Figure
 
4.13C, E), 
while apparent plaque was observed in B cells SV40 infected of 60-d.p.i. samples (Figure 4.13 
D,F). CV-1 cells infected at moi 10
6
pfu/ml was used as positive control. As anticipated, no plaque 
was observed in uninfected CV-1 cells used as negative control (Figure 4.13B).  
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Table 4.5: viral titers determined in CV-1 permissive cell monolayers (106 cells/monolayer) 
using 50% Estimated Endpoint dilution technique. B+SV40( B cells SV40 infected), B+pSV3neo(B 
cells pSV3neo transfected). 
Figure 4.13: C.P.E observed in B infected and transfected cells with CV-1 
monolayers.) AB, CV-1 positive control, D, CV-1 uninfected monolayer-negative control, 
C,E, F, B cell pSV3neo transfected of 10 and 40 p.i respectively. G,H,I, B cell SV40 strain 
776 infected cells of 10, 40 and 60p.i respectively. J,K,L, medium of  B infected cells of 10, 
40, and 60 p.i. 
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Figure 4.14: Plague assay, A (CV-1 infected with SV40- control positive), 
B (CV-1 uninfected cell-negative control), CD (B cell SV40 infected of 10 p.i) E,F 
(B cell SV40 transfected of 60 p.i) . Magnification 20x.                 
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 5 Discussion 
 
 
Cellular transformation and tumorigenic activities of oncogenes have been intensively investigated 
(113, 114). Evidence of an association between SV40 infection and  human cancers has been 
accumulated during the past 40 years with its major controversy dividing the research community in 
pro/counter groups. Numerous questions have been imposed by some  investigators concerning the 
association of SV40 with human diseases, thereby jeopardizing further serious investigation 
concerning SV40 and certain human cancers. However, many investigations have been carried out 
on the mechanisms of transformation of  SV40 Tag in animal and human cells; on cell 
differentiation and on the ability of SV40 Tag to bind and inactivate p53.  
 
Although the past few years have witnessed a large number of publications on the presence of SV40 
sequences in human tumors, surprisingly little information exists on the proportion of SV40 
infection in the blood of healthy individuals (40a,  23).
 
 The published frequency of SV40 DNA in 
normal tissues or in people without cancer is quite variable. In Italy, different studies have found 
different frequencies of 13%, 23%, and 29% though some study groups failed to find any positive 
control samples among their subjects.  In (experiment 1) of this work, a total of 17% positivity for 
SV40 was observed from buffy-coats of 60 healthy individuals from Aviano using the nested PCR 
approach. Notwithstanding the low frequency of SV40 sequences in this study, the data confirms 
and extends previous results on the presence of SV40 sequences in DNA from different cohorts of 
healthy blood donors in Italy. 
 
 
 
Additionally, the study is in support of the evidence that SV40 is circulating among healthy 
individuals and this calls for further research in larger cohorts, and from different global regions, so 
as to resolve the issue of how and when SV40 infection occurs among humans and to investigate 
the routes of infection.   
72 
  
While recent reports suggest the presence of SV40 DNA sequences in different lymphoproliferative 
disorders, little is known about the main interaction of SV40 with lymphocyte  cells. Hence, this 
study further investigated the interaction between SV40 and B/T lymphocytes to verify if SV40 
infects, transforms, and immortalizes B cells. 
 
Isolated and purified B and T cells were found to be positive for CD19 with anti-CD45 and anti-
CD3 (Table 4.1). Although little variations in % expression of cells and almost no statistically 
significant variation was observed in percentage population of the 6 donors (Figure 4.4) using FACs 
analysis, this experiment shows that the collected buffy coat of the healthy blood donors and the 
subsequent purified B and T cells were normal, implying that with this percentage expression rate, 
problems opposed by variability in different donors is ruled out in the experiment. In effect, the use 
of primary human lymphocyte B and T cells could also offer more mechanistic insight than already 
existing immortalized B cell lines.  
 
Proliferation and viability capacity of the infected and transfected B/T lymphocytes were analyzed 
from 5-d.p.i. using trypan blue and alamar blue assays. Both pSV3neo and wild strain 776 SV40 
induced proliferation with more than 100%  increase in cell survival when compared to uninfected 
B and T lymphocytes (Figures 4.1 and Figure 4.5). The cell survival graph indicated that the 
proliferation and viability capacity of normal B cells to survive in culture lies between 1 to 5 days.   
The data showed that, the pattern of infection in B and T cells  is in line with the semi-permissibility 
usually depicted by SV40 in human cells (3, 4). It proofs to be efficient strategy to infect 
lymphocytes notwithstanding the drastic fast reduction/death of the infected cells in culture.  
Though, the cells experienced cell death, the little number of cells that passed crisis stage continued  
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 to multiply up to 80-d.p.i. in T cells and after 80-d.p.i. in B cells with the same pattern of initial cell 
increase and decline experienced in early stage of proliferation. While increase in cell proliferation 
was observed in B and T lymphocytes infected with SV40 than in B lymphocyte transfected with 
pSV3neo, a slight retention of cells in culture was observed in the later than the former.  
 
Increased proliferation reflects the alteration in cell cycle control and extension of life span of cell 
when the cells are transformed (115).  Probably, B and T lymphocytes infected with wild SV40 
strain were affected more by culture stress than pSV3neo transfected cells. With this, the infected 
lymphocytes tend to fall into the third characteristics of transformed cells that ―experience more cell 
death due to cultural stress and tends to be more tumorigenic if inoculated to animal models‖ (115). 
This effect of the virus may play a role in cancer development and may support the hypothesis that 
additional factors may be required to act in synergy with SV40 infection for the induction of a 
cancerous process in lymphocytes. In other cancer types, the role of an SV40 co-factor is strongly 
indicated. It has been suggested that SV40 is a co-carcinogen with asbestos in the development of 
malignant mesothelioma as demonstrated  in vitro with human mesothelial cells (3). Another 
example is the risk of developing HBV—including liver cancer, greatly increased by other co-
factors such as the hepatotoxin aflatoxin (169). 
 
 
Nacchtigal et al.,(1990) found pSV3neo to be a stable transfection plasmid with lipofectamine.  
Similarly, our results showed that B lymphocytes can be stably transfected with the pSV3neo, an 
SV40 Tag coding plasmid.  
 
Similarly, the alamar blue assay results/data (Figure 4.6) also depicted cell viability with increased 
cell viability at early stage of post infection (3-d.p.i.) before drastic fall in graph row, signifying cell 
death experienced at 30-d.p.i. Unlike infected and transfected cells, decrease in reduction of alamar 
blue was observed in normal B cells from 3-d.p.i. (Figure 4.6, E). Although percentage survival in  
ii 
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 B cells infected with wild SV40 were higher than B cells transfected with pSV3neo, yet pSV3neo 
transfected cells depicted slight higher percentage of alamar blue reduction at 30-d.p.i. than B cells 
infected with wild-type 776 SV40 strain. Nevertheless, both results showed reduction in viability at 
30-d.p.i. which suggest a certain degree of inhibitory response in these cells. 
Alamar blue (AB) is  among the vital dyes which are non-toxic to cells and offer the advantages of 
keeping the cells in culture to observe changes over time. AB has been utilized in various tests such 
as, measuring the proliferation of human lymphocytes, primary rat hepatocytes, various human cell 
lines, in measuring cell-mediated cytotoxicity of human T lymphocytes, as well as cell viability in 
BeWo and JEG-3 choriocarcinoma cells (154). 
 
Furthermore, to have more insight in the transfected and infected B cells growth behavior, their 
population doubling time was observed. This experiment was carried out at least three times, for 
accuracy confirmation. B cells SV40 infected was found to grow at approximately one doubling 
every 26 hours with growth rate of 0.0255 based on quantification of cell number using microscope 
counting. The transfected B cells make one doubling every 27 hours with growth rate of 0.0247. 
Additionally, the cells exhibited a short resting phase in culture that normally leads to cell 
doubling/increase. This characteristics is described by Kim et al as a resting phase (G0) shown by 
cells that have temporally stopped dividing (156). This suggests that the drastic reduction in number  
experienced by B cells infected and transfected  at 80-d.p.i. in culture was not actually cell death 
rather resting (G0) phase that gave rise to cell increase after 80-d.p.i. 
 
Another key feature in analyzing the ability of SV40 to infect human lymphocytes is the replication 
of viral DNA. SV40 DNA sequences was measured during the infection time course from 3-80 days 
post infection for T cell and  3-100 days for B cells by single PCR using primers specific to SV40. 
In the infected and transfected cells throughout their period in culture, SV40 sequences were 
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 detected and this suggested stable integration of the SV40 Tag in the infected and transfected B and 
T cell samples.  
 
Previous and recent studies have implicated SV40 in different human cancers such as 
mesothelioma, brain tumors and NHL diseases (39, 40a,  90, Table 1.2), and have regularly detected 
its DNA sequences in healthy blood donors. Malignant pleural mesothelioma (MM) is a fatal 
human tumor and its onset is related to asbestos fiber inhalation, which is a tumorigenic natural 
mineral and an immunosuppressor agent (171, 172). According to investigating research studies, 
prediction of the number of patients who will die of MM in Western Europe each year, will almost 
double over the next 20 years with a total of about 250,000 death until 2029 before experience in 
decline (173). SV40 has long been identified as a co-carcinogenic factor with asbestos in the 
proliferation of mesothelioma. Additionally, NHL disease incidence have dramatically increased in 
the last 30 years with an 80% increase in the US noted between 1973 and 1997 (143). The reasons 
for the increase in incidence are not fully understood. However, many different viruses with 
oncogenic potentials have been found to be associated with non-Hodgkin lymphoma, including 
SV40 (174, Table 1.2). 
 
The continuous detection of SV40 DNA sequence in B and T cells infected and transfected 
throughout the time course with PCR technique in this experiment is a strong support to previous 
studies that detected SV40 sequences in their experiment. The time course of this particular 
experiment was repeated a number of times to confirm results and elimination of possible 
contamination.  Although, mounting  evidence  supporting  SV40 DNA prevalence in human 
cancers is building up, many groups failed to detect SV40 in their experiment in different human 
cancers like brain tumors, mesothelioma and lyphoproliferative disorders (128, 148). This was 
attributed to some PCR results with contamination of common laboratory plasmids containing 
SV40 sequences. The positivity of SV40  DNA sequences in this present experiment confirms that  
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 not all investigators that reported SV40 positive results contaminated their results. Nevertheless, 
some SV40 negative reports can be attributed to geographical and population factors,  while other 
negative reports possibly resulted from technical limitations in the laboratory. A particular research 
team which has consistently challenged the presence of SV40 in human tumours and has reported 
negative findings, has recognized sensitivity problems that raise questions about these negative 
reports (175). 
  
Expression of Tag and VP1 seems to be one of the most important analysis to confirm SV40 
infection and transformation. The in vitro detection of SV40 Tag in SV40 infected and transfected 
B and T cells is a key finding in the study of SV40 involvement in lymphomagenesis. The Tag 
indicates  expression of viral early genes. In fact, Tag detection in transfected and infected B cells 
up to 90-d.p.i. suggested the real integration of SV40 infection into the genome of B cells even at 
crisis stage. pSV3neo transfected cell expressed almost nuclear expression of Tag in the 
immunoflourescence experiment with its absent in the RT-PCR experiment. B and T cells SV40 
infected expressed both Tag and VP1 in immunoflourescence analysis and Tag up to 20 and 40-
d.p.i. in RT-PCR respectively. Two reasons can be  responsible for the absence of SV40 Tag in the 
RT-PCR experiment: (a) the transcribed RNA is probably too small to be detected with used 
parameter in transfected cells since low viral load  has been known to be associated in most SV40 
infected lymphocytes as observed in (38). (b) SV40 may be exhibiting the ―heat and run‖ nature of 
infection in pSV3neo transfected B cells but only functions by initiating the infection. Subsequent 
progression of infection sees Tag as not necessary since it has fulfilled its role in initiating the 
infection/transformation process. This mechanism has been proposed in relation to SV40-associated 
lymphoma development based on the finding of higher SV40 prevalence in reactive 
lymphadenopthies than in overt lymphoma, supporting a role for the virus in the early phases of 
lymphomagenesis (176).  
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  B and T cells SV40 infected showed both nuclear and cytosol expression of VP1 at 8-d.p.i. which 
was absent in pSV3neo due to its consisting of only early region genes of SV40. Additionally, this 
difference in B cells transfected and infected response could be due to genetic differences between 
the two B cell lines. The plasmid virus, with its increased expression of Tag, suggests that Tag is 
playing a role in the observed expression changes and may hint a potential function of Tag to 
participate in immune evasion.  
 
Studies have observed that  SV40 Tag is required for viral replication and cellular transformation, 
and is only expressed after entry into a host cell (109). Therefore, analyzing Tag expression in 
infected and transfected B lymphocytes in this experiment is a critical component in testing the 
hypothesis that SV40 plays a role in human lymphomagenesis.  
 
The adoption of two detection methods in this experiment, for evidence of SV40 as applied in 
recent  studies: a PCR-based method and immunohistochemical staining for Tag. The agreement of 
these two independent detection methods almost guarantees against laboratory contamination  being 
responsible for the presence of SV40 (11). 
 
 Studies have detected that several DNA viruses encode unique oncoproteins that target pRb and 
p53 popularly known as ―tumor suppressor gene‖, emphasizing the central power these two proteins 
exert over cell cycle control.  SV40 Tag is the only viral oncoprotein with the ability to interact with 
both p53 and pRb family members, underlining its potency and power as a multifunctional 
transforming protein. Complex-formation of p53 and pRb with Tag has been observed in SV40-
positive brain tumours and mesotheliomas. Similarly, the co-incident detection of SV40 Tag and 
p53 alterations in SV40 infected lymphocytes and lymphoma diseases as well would be informative 
(177).  Furthermore, immunoflourescenc technique was  used to detect the p53 expression in SV40 
infected B cells in this study. Using PAB240 antibody as primary with FITC conjugated secondary 
antibody specific for human p53.  p53 expression was observed at the cytoplasm and nucleus  of the 
78 
 normal  B cells as observed by (178)[Figure not shown],  but absent in the infected, tranfected B 
cells. The full thick staining of the Dapi staining of  p53 in the normal B cells was also absent in the 
W138-VA13 (positive control). This data suggested the possibility of p53 being disactivated in the 
SV40 infected and transfected B cells and its transformation caused by the presence of SV40 Tag 
(49). The short coming of this experiment was  its failure to use a cell line known to express p53 as 
a second positive control. This therefore, is strongly recommended for future work as this will 
clarify and firmly confirm result.  It is of note that the tumour suppressor proteins p53 and pRb are 
commonly lost, over expressed  or mutated in human tumours.  The SV40 transforming mechanism 
in binding of Tag to p53 and pRb proteins is  similar to the  functional role of SV40 in 
lymphomagenesis because the functional inactivation of genes that monitor genome integrity is a 
trait of lymphomas (23). This has particularly been observed in patients with diffused large B cell 
lymphoma and follicular lymphomas, which are the two types of NHL in which SV40 most 
frequently found, often have detectable p53 alterations.  
 
While the precise mechanism of SV40 transformation and immortalization has not yet been fully 
clarified, its Tag is known to allow cells to bypass the G1 cell cycle block, most likely by 
interacting with p53 and pRb tumor suppressor proteins. The complex formation between Tag and 
these cellular proteins leads to the inactivation of these tumor suppressor gene products, resulting in 
unregulated DNA replication and cell division. It is very likely that SV40 T antigen–mediated 
inactivation of pRb and p53 pathways extends the B cell lifespan which gave rise to its 
transformation and perhaps short immortalization. However, the life cycle of B cells infected by 
SV40 has been proposed to last up to 4-6 months in culture (38).  
 
In lymphomagenesis disorders, chromosomal translocations and structural aberrations of cells are 
the most frequently recognized oncogenic events (176). Indeed, ultrastructural verification of B and 
T infected and transfected cells with TEM depicted different abnormal formations in the DNA, 
cytoplasm, vacuoles and cell wall right from 3-d.p.i. in infected B cells (Figure 4.11). Generally, B 
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 cells transfected and infected depicted features distinguished in other SV40 infected lymphocytes 
and in lymphomagenesis disorders such as Leukemia, Hodgkin diseases, and HTLV-1 infected cells 
(161, 167, 168). This result strongly confirmed transformation of the B and T cells by wild SV40 
strain and pSV3neo plasmid. 
 
Additionally,  from the immunoflourescence results, an interesting observation was noted in terms 
of morphological aspect. At day 8-50 d.p.i., 20% of the SV40-infected B and T cells displayed large 
B cell morphology with dense SV40 VP1 staining in the cytosol compartment (Figure 4.b and 
Figure 4.10). This morphological structure of large B and T cells reminds that of Large Cell 
Lymphoma (LCL), which is very cantankerous and rapidly rising cancer of either B-or T-cells. LCL 
is known to be one of the most common types of lymphoma, accounting for 31% of all non-
Hodgkin’s disease (179). 
 
Vertical and horizontal transmissions have been postulated as additional possible sources of 
infection along with proliferation of archetypal and non archetypal SV40 transmission (39). It has 
been postulated that SV40 is transmitted through environmental contact. Indeed, it has been shown 
that this virus is present in the urine, stool, tonsil and blood specimens of children and adults, 
suggesting different ways of transmission, such as urine, oro-foecal, respiratory and haemapatic 
routes are responsible for SV40 infection. The observation of this present study is in support of the 
results obtained by past studies on subjects administered with SV40-contaminated vaccines by 
different routes. In fact, SV40 was detected in these subjects after a number of weeks or days in 
their stools and tonsils depending on oral or nasal spray administration of contaminated vaccines 
(39, 104). 
 
Indeed, SV40-infected human B and T cells produced SV40 viral progeny, from  10 to 60-d.p.i., 
with different titers. SV40 induced lyses in almost 80% of B and T cells in culture. Our 
experimental data indicate that infected human B and T cells are virus progeny producers, but then 
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 they lose the ability to shed the virus later than 60-d.p.i.  It is therefore possible that before the 
―crisis‖ stage, SV40 induces an ―acute‖ infection in human B and T cells, which is somehow 
controlled by those cells which take over during the crisis, resulting in a sort of persistent infection. 
Interestingly, this result indicate that  B and T cells can be infected by SV40, while the lifespan of B 
and T cells, which resisted the lyses, is greatly extended. In reality,  normal human B cells from 
healthy blood donors have been distinguished to proliferate in culture roughly eight days. SV40 
DNA persisted in infected and transfected B and T cells, as indicated by the presence of Tag 
sequences. 
 
The etiology of the many different types of lymphoma is multi-factorial in nature, and viruses have 
been shown to be involved in some cases. Given the strong oncogenicity of SV40, if it is present in 
human lymphocytes then it could possibly function as a co-factor in lymphomagenesis. The 
indication of a co-carcinogenic role for SV40 is further strengthened given that this theory has been 
proven for other transforming viruses. For instance, EBV has long been linked with Burkitt's 
lymphoma but presence of the virus is only one factor involved in disease development (180).  
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 CONCLUSION 
Although limited in size, the study of 60 subjects from Aviano, gives an epidemiological support of 
presence/prevalence of SV40 in the PBMC of healthy donors from Aviano. The findings of this 
study is similar to those of  SV40 prevalence detected previously by earlier studies carried out in 
blood specimen of healthy subjects, not minding the difference in frequencies, which may be due to 
the employment of different protocols. Furthermore, the study suggests that oncogenic SV40 virus 
is being disseminated in the human population. Further research in larger cohorts, and from 
different global regions, is needed to resolve the issue of how and when SV40 infection enters and 
spreads among the human species. This will also help to reduce the predicted incidence rate of 
250,000 cases of mesothelioma over the next 40 years. Obviously, the use of SV40 as a diagnostic 
marker in mesotheliomal cancers and asbestos is promising and this encourages epidemiological 
molecular study to help in bringing SV40 closer to clinical practice.  
 
Relating SV40 with human B and T cells denotes an innovative that should be put into 
consideration when assessing the biological activity of this viral agent in the human host. The 
characteristics of SV40 in B and T cells indicate the possibility of natural SV40 infection in humans 
and calls for further investigation especially in hematological diseases and other malignancies that 
involves oncogenic viruses such as HTLV-1, EBV and HIV.  More studies  in human T  and B cells 
with SV40 infections are necessary to test the specificity of the relationship of SV40 with 
lymphoproliferative disorders. 
 
Indeed, human B and T cells are semi permissible to SV40 infection and can last in culture between 
4-6 months as speculated before in (38).  In this study, the SV40 infected lymphocyte cells have 
depicted the usual characteristics of transformed cells as proposed in (115), though how 
tumorigenic the infected and transfected cells are, is yet to be revealed. Inasmuch as a full 
transformation of infected/transfected B cells have been achieved in this study, my data therefore 
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 suggests that SV40 may play a role in lymphomagenesis and in spreading the virus to other organs 
in the body. Additional investigations are needed to establish whether  SV40 act together with co-
factors, including micro-environmental, genetic and epigenetic factors in the B  cell transformation.  
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 ABBREVIATIONS 
 
                                                                    
  AB 
APCs 
AHW   
ALW 
BB2-BB3        
B+ SV40            
B +pSV3neo      
BKV 
Alamar Blue 
Antigen presenting cells 
Absorbance of higher wavelength 
Absorbance of lower wavelength 
SV.for1-SV.rev 1 primers 
SV40 infected B cells 
pSV3neo transfected B cells 
BK virus 
CTL Cytotoxic T lymphocyte 
CBP 
cDNA 
CREB 
C.P.E 
DEPC 
DMEM 
d.p.i 
DNA 
dsDNA 
DLBCL 
EBV 
EL cells 
EMEM 
EDTA 
ER 
FACs 
FBS 
FITC 
HCMV 
HGF 
HTLV-1 
HIV 
CREB-binding proteins 
Complementary Deoxyribonucleic acid 
cAMP regulatory element binding proteins 
Cytopathic effect 
diethylpyrocarbonate 
Dulbeccon modified minimal essential medium 
Days of post infection 
Deoxyribonucleic acid 
Double stranded deoxyribonucleic acid 
Diffuse large B-cell type lymphoma 
Epstein- Barr virus 
Extended life cells 
Eagles minimal essential medium 
Ethylenediaminetetraacetic acid 
Endoplasmic reticulum 
Fluorescence Activated Cell Sorting 
Foetal Bovine Serum 
Fluorescein isothiocyanate 
Human Cytomegalovirus 
Hepatocyte growth factor 
Human T Lymphotropic virus type-1  
Human Immunodeficiency virus 
I cells                  Immortalized cells 
IPV                     Inactivated polio vaccines 
JCV                    JC Virus 
JNK                    Jun N-terminal Kinase 
KIV                    KI virus 
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 KSHV 
LPV 
MAPK 
MCV 
MHC 
miRNA 
MOI 
MPM 
MuPyV 
MW 
Kaposi’s Sarcoma Herpes virus 
Lymphotropic polyomavirus 
Mitogen Activated Protein Kinase  
Merkel Cell Virus 
Major Histocompatibility Complex 
Micro ribonucleic acid 
Multiplicity of Infection 
Malignant Pleural Mesothelioma 
Murine Polyomavirus 
Molecular weight marker 
NHL                  Non-Hodgkin’s  lymphoma 
NK cells 
NLS 
NPC 
nPCR 
OPV 
P13K 
PBMCs 
PCR  
PDT 
PFU 
PHA 
PML 
PP2A 
p53 
pRb 
RNA 
RO 
RPMI 
RT 
RT-PCR 
SEM 
SIV 
SV40 
Tag /LT 
tag /ST 
TEM 
T +SV40 
VEGF 
VEGFR 
VP1 
WUV 
Natural killer cells 
Nuclear Localization Signal 
Nuclear pore complex 
Nested Polymerase chain reaction 
Oral Polio vaccine 
Phosphatidylinositol 3-kinase 
Peripheral blood mononuclear cells 
Polymerase chain reaction 
Population doubling time 
Plague forming units 
Phytohemagglutinin 
Progressive multifocal leukoencephalopathy 
Protein phosphate 2A 
tumor protein 53 
retinoblastoma protein 
Ribonucleic acid 
Correction factor 
Roswell Park Memorial Institute Medium 
Room temperature 
Reverse-transcriptase polymerase chain reaction 
Scanning electron microscope 
Simian immunodeficiency virus 
Simian virus 40 
Large T antigen 
Small T antigen 
Transmission Electron Microscope 
SV40 infected T cells 
Vascular endothelial growth factor  
Vascular endothelial growth factor receptor 
Viral protein 1 
WU virus 
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